Wednesday Research Poster Presentations

POSTER SESSION V:  Poster Display Hours – 8:00AM - 1:30PM
Post Author Discussion Hour – 12:30PM - 1:30PM

<table>
<thead>
<tr>
<th>PRM:</th>
<th>RESEARCH ON METHODS</th>
<th>ROWS A-H</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHS:</td>
<td>HEALTH SERVICES</td>
<td>ROWS H-P</td>
</tr>
</tbody>
</table>
## Research Poster Presentations – Session V

<table>
<thead>
<tr>
<th>Acceptance Code</th>
<th>VIH Page #</th>
<th>Topic – Subtopic</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRM1–PRM27</td>
<td>A310</td>
<td>Research on methods – Clinical Outcomes Methods</td>
</tr>
<tr>
<td>PRM28–PRM41</td>
<td>A315</td>
<td>Research on Methods – Cost Methods</td>
</tr>
<tr>
<td>PRM42–PRM64</td>
<td>A318</td>
<td>Research on Methods – Databases &amp; Management Methods</td>
</tr>
<tr>
<td>PRM65–PRM106</td>
<td>A322</td>
<td>Research on Methods – Modeling Methods</td>
</tr>
<tr>
<td>PRM107–PRM149</td>
<td>A330</td>
<td>Research on Methods – Patient-Reported Outcomes Studies</td>
</tr>
<tr>
<td>PRM150–PRM161</td>
<td>A338</td>
<td>Research on Methods – Statistical Methods</td>
</tr>
<tr>
<td>PRM162–PRM176</td>
<td>A340</td>
<td>Research on Methods – Study Design</td>
</tr>
<tr>
<td>PRM177–PRM195</td>
<td>A343</td>
<td>Research on Methods – Conceptual Papers</td>
</tr>
<tr>
<td>PHS1–PHS30</td>
<td>A346</td>
<td>Health Services – Clinical Outcomes Studies</td>
</tr>
<tr>
<td>PHS31–PHS86</td>
<td>A352</td>
<td>Health Services – Cost Studies</td>
</tr>
<tr>
<td>PHS87–PHS103</td>
<td>A362</td>
<td>Health Services – Patient-Reported Outcomes &amp; Patient Preference Studies</td>
</tr>
<tr>
<td>PHS104–PHS208</td>
<td>A365</td>
<td>Health Services – Health Care Use &amp; Policy Studies</td>
</tr>
<tr>
<td>PRM</td>
<td>A</td>
<td>Title</td>
</tr>
<tr>
<td>-------</td>
<td>-----</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>PRM2</td>
<td>A2</td>
<td>EFFECT OF ICD-10 TRANSITION ON PATIENT IDENTIFICATION AFTER ONE YEAR IN A US MANAGED CARE DATABASE</td>
</tr>
<tr>
<td>PRM3</td>
<td>A3</td>
<td>A METHODOLOGY FOR EVALUATING PRIMARY NONADHERENCE USING ANNONOMIZED RETROSPECTIVE ELECTRONIC MEDICAL RECORDS AND PRESCRIPTION CLAIMS DATABASES</td>
</tr>
<tr>
<td>PRM4</td>
<td>A4</td>
<td>EVALUATION OF A CUSTOMIZED COMPLIANCE PROGRAM FOR ORAL ONCOLOYTHERAPY FOR LEUKEMIA</td>
</tr>
<tr>
<td>PRM5</td>
<td>A5</td>
<td>REAL-WORLD EVALUATION SCREENING STUDY AND REGISTRY OF DYSKINESIA IN PATIENTS TAKING ANTIPSYCHOTIC AGENTS: THE RE-KINECT STUDY</td>
</tr>
<tr>
<td>PRM6</td>
<td>A6</td>
<td>ESTIMATION OF SURVIVAL OUTCOMES FOR USE IN ONCOLOGY VALUE FRAMEWORKS</td>
</tr>
<tr>
<td>PRM7</td>
<td>A7</td>
<td>INSULIN IS MOST APPROPRIATE COMPARATOR TO GLP-1 RECEPTOR AGONISTS AND DPP-4 INHIBITORS IN REAL-WORLD CARDIOVASCULAR OUTCOME STUDIES</td>
</tr>
<tr>
<td>PRM8</td>
<td>A8</td>
<td>AN INDIRECT TREATMENT COMPARISON OF UNAPPROVED TREATMENT OPTIONS OF ALZHEIMER’S DISEASE FOR RESEARCH PRIORITIZATION</td>
</tr>
<tr>
<td>PRM9</td>
<td>A9</td>
<td>THE POTENTIAL OF ELECTRONIC HEALTH RECORD DATA TO OPTIMIZE RECRUITMENT EFFICIENCY IN CARDIOVASCULAR OUTCOME TRIALS</td>
</tr>
<tr>
<td>PRM10</td>
<td>A10</td>
<td>USE OF INTERMEDIATE CLINICAL ENDPOINTS (ICE) AS A PRIMARY EFFICACY ENDPOINT IN MALIGNANT MELANOMA</td>
</tr>
<tr>
<td>PRM11</td>
<td>A11</td>
<td>EFFECT OF EDUCATIONAL INTERVENTION TOOL IN KAP SCORE DIFFERENCES AMONG ADULT RESPONDENTS AT THREE TIME POINTS.</td>
</tr>
<tr>
<td>PRM12</td>
<td>A12</td>
<td>INSULIN SHOULD BE COMPARED TO INCRETIN ENHANCERS INSTEAD OF OTHER ANTI-DIABETES MEDICATIONS IN SAFETY AND OUTCOMES STUDIES</td>
</tr>
<tr>
<td>PRM13</td>
<td>A13</td>
<td>BURDEN OF ANEMIA AMONG EVER-MARRIED WOMEN IN BANGLADESH: DOES HOUSEHOLD ECONOMIC INEQUALITY MATTER? HOW DEMOGRAPHICS, DIABETES, MATERNITY AND BMI DECOMPOSE ON THE ANXIETY?</td>
</tr>
</tbody>
</table>
PRM14 A14 USING ITERATIVE USER EXPERIENCE DESIGN TO IMPROVE ELECTRONIC CLINICAL OUTCOMES ASSESSMENT DATA QUALITY
Butler A1, Feaster T2, Miller DS2, Barbone JM1, Bracket, Wayne, PA, USA, 2Bracket, wayne, PA, USA

PRM15 A15 ASSESSMENT OF REAL-WORLD DATA SURROGATE FOR THE RESPONSE EVALUATION CRITERIA IN SOLID TUMORS (RE objectives) values
Feinberg BA1, Klink AJ1, Ernst FR1, Weltz M2, Nabhan C1, 1Cardinal Health, Dublin, OH, USA, 2Alvin and Lois Lapidus Cancer Institute, Baltimore, MD, USA

PRM16 A16 ESTIMATING COSTS ASSOCIATED WITH EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) – A RANGE OF ALGORITHMS
Buikema AR1, Fox KM2, DePietro M2, McPheeters JT1, Fang Y1, Cao F1, Elliott C1, Bengtson LG1, 1Optum, Eden Prairie, MN, USA, 2AstraZeneca, Wilmington, DE, USA

PRM17 A17 ESTIMATING GLOMERULAR FILTRATION RATE IN PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASES IN EUROPE
Jouaville SL1, Bizouard G1, Boutmy E1, Keja J2, 1QuintilesIMS, Boulogne Billancourt, France, 2QuintilesIMS, Rotterdam, The Netherlands

PRM18 A18 TOWARDS OPTIMIZED ONCOLOGY CLINICAL TRIAL DESIGN: A PLATFORM TO ASSESS THE SENSITIVITY OF CLINICAL ENDPOINTS TO MAXIMIZE DRUG VALUE
Chawla A1, Cho Y2, MacKenzie A1, 1Precision for Value, Boston, MA, USA, 2Precision for Value, New York, NY, USA

PRM19 A19 QUANTIFYING THE HEALTH OUTCOMES OF MARKET ACCESS POLICIES – USING SIMULATION MODELING TO COMPARE ACCESS TO CANCER MEDICINES ACROSS GLOBAL MARKETS
Su W1, Lockwood C2, Chui C3, Vandigo J4, Haninger K4, IHS Markit, Washington, DC, USA, 2IHS Markit, Santa Clara, CA, USA, 3IHS Markit, London, UK, 4Pharmaceutical Research and Manufacturers of America (PhRMA), Washington, DC, USA

PRM20 A20 TO RE-CENSOR, OR NOT TO RE-CENSOR, THAT IS THE QUESTION: CRITICAL CONSIDERATIONS WHEN APPLYING STATISTICAL METHODS TO ADJUST FOR TREATMENT SWITCHING IN CLINICAL TRIALS
Latimer N1, Abrams KR2, 1University of Sheffield, Sheffield, UK, 2University of Leicester, Leicester, UK

PRM21 A21 OPTIMAL DESIGN OF PRE-AUTHORIZATION TRIALS FOR EFFECTIVENESS EVALUATION IN SCHIZOPHRENIA
Karcher H1, Fu S2, Zöllner Ankarfeldt M3, Haro JM4, Nordon C5, LASER Analytica, London, UK, 2LASER Analytica, Loerrach, Germany, 3Copenhagen University Hospital, Hvidovre, Denmark, 4Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain, 5LASER Analytica, Paris, France

PRM22 A22 APPLICABILITY OF APPLE RESEARCH KIT TO DELIVER COGNITIVE TESTING IN CLINICAL TRIALS: RESULTS OF A PILOT STUDY
Byrom B1, Simpson L2, Lee J3, Flood E4, Cassidy C4, Gadala-Maria A3, Muehlhausen W2, McCarthy M5, Skerritt B1, 1ICON Clinical Research, Marlow, UK, 2University of Nottingham, Nottingham, UK, 3mProve Health, Arlington, VA, USA, 4ICON Clinical Research, Gaithersburg, MD, USA, 5ICON Clinical Research, Dublin, Ireland

PRM23 A23 PATIENT ATTITUDES AND ACCEPTABILITY TOWARDS USING THEIR OWN MOBILE DEVICE TO RECORD PATIENT REPORTED OUTCOMES DATA IN CLINICAL TRIALS
Byrom B1, Muehlhausen W1, Flood E2, Cassidy C2, Skerritt B3, McCarthy M1, 1ICON Clinical Research, Marlow, UK, 2ICON Clinical Research, Gaithersburg, MD, USA, 3ICON Clinical Research, Dublin, Ireland

PRM24 A24 REAL WORLD EVIDENCE AND NETWORK META-ANALYSES: A SYSTEMATIC LITERATURE REVIEW OF EVIDENCE SYNTHESIS METHODS COMBINING DIFFERENT STUDY DESIGNS
Mesana L1, Pacou M2, Gauthier A1, 1Amaris, London, UK, 2Amaris, Paris, France

PRM25 B1 SURVIVAL TREND AND IMPACT OF ADVERSE DRUG REACTIONS DURING HAART ON SURVIVAL FUNCTION IN HIV/AIDS PATIENTS
Khan K1, Khan AH2, Sulaiman SA2, Soo CT3, Ahmed SI4, 1Universiti Sains Malaysia, Pulau Pinang, Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia, 3General Hospital Penang, Pulau Pinang, Malaysia, 4International Medical University, Kuala Lumpur, Malaysia

PRM26 B2 EVALUATION OF PHARMACIST'S EDUCATIONAL AND COUNSELING IMPACT ON PATIENTS' CLINICAL OUTCOMES IN A DIABETIC SETTING
Ojisebu WA1, Bello SI2, Saka AS1, 1Olabisi Onabanjo University, Sagamu, Nigeria, 2University of Ilorin, Ilorin, Nigeria

PRM27 B3 DEVELOPING AN ICD-10-CM VERSION OF CHARLSON COMORBIDITIES FOR UNITED STATES REAL-WORLD HEALTHCARE DATA
Beyrer J, Nolot S, Haldane DC, Johnston J, Eli Lilly and Company, Indianapolis, IN, USA
RESEARCH ON METHODS - Cost Methods

PRM28  B4  THE APPLICATION OF RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IN SECONDARY PREVENTION OF CHEMOTHERAPY INDUCED THROMBOCYTOPENIA PATIENTS IN CHINA
Yang F1, Li L2, Xuan J3,1Shanghai Centennial Scientific Ltd, Shanghai, China, 2Fudan University, Shanghai, China, 3Sun Yat-Sen University, Guangzhou, China

PRM29  B5  A METHOD FOR IDENTIFYING LONG-TERM CARE USE IN CLAIMS DATA
Hanna ML1, Kim D1, Albrecht J2, Perfetto EM3,1University of Maryland, School of Pharmacy, Baltimore, MD, USA, 2University of Maryland, School of Medicine, Baltimore, MD, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA

PRM30  B6  CONSIDERATIONS IN THE ECONOMIC EVALUATION OF NURSE PRACTITIONERS AND CLINICAL NURSE SPECIALISTS ROLES
Lopatina E1, Donald F2, DiCenso A3, Martin-Misener R4, Kilpatrick K5, Bryant-Lukosius D3, Carter N3, Reid K6, Marshall DA7,1University of Calgary, Calgary, AB, Canada, 2Ryerson University, Toronto, ON, Canada, 3McMaster University, Hamilton, ON, Canada, 4Dalhousie University, Halifax, NS, Canada, 5Université de Montréal, Montréal, QC, Canada, 6KJResearch, Rosemere, QC, Canada, 7Alberta Bone and Joint Health Institute, Calgary, AB, Canada

PRM31  B7  THE IMPACT OF NON-DIVISIBILITY, DIMINISHING MARGINAL RETURNS TO SCALE AND NON-MARGINAL BUDGET IMPACT ON THE COST-EFFECTIVENESS THRESHOLD
Paulden M1, McCabe C2, University of Alberta, Edmonton, AB, Canada

PRM32  B8  A STATISTICAL ANALYSIS PLAN TO UNDERSTAND OSTEOARTHRITIS PATIENT JOURNEY BY LINKING MEDICARE CLAIMS ACROSS CARE DELIVERY SETTINGS
Su W1, Chen F1, Iacobucci W1, Bedenbaugh A2, Bair N3, Oruc A2,1IHS Markit, Washington, DC, USA, 2Samumed, San Diego, CA, USA

PRM33  B9  COST SAVINGS FROM REDUCED PROLONGED AIR LEAK DUE TO THE APPLICATION OF POWERED ENDOCUTTERS IN VIDEO-ASSISTED THORACOSCOPIC LUNG RESECTION PROCEDURES: A REAL-WORLD EVIDENCE STUDY IN CHINA
Kong L1, Kong W1, Liu Q2, Xuan J3, Johnson & Johnson’s (CHINA), Shanghai, China, 2Beijing Brainpower Pharma Consulting Co. Ltd, Beijing, China, 3Sun Yat-Sen University, Guangzhou, China

PRM34  B10  ECONOMIC VALUATION OF AVOIDABLE MORTALITY IN THE CARIBBEAN REGION OF COLOMBIA
Arrieta Arrieta A1, Florez Tanus A2, Correa Reyes J1, Alvis Guzman N3,1Universidad de Cartagena. Alzak Foundation, Cartagena de Indias, Colombia, 2Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoléon Franco Pareja. Centro de Investigación e Innovación en salud, Cartagena de Indias, Colombia, 3ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia

PRM37  B13  COMPARISON OF PREDICTIVE MODELING OF COST AND HEALTH CARE UTILIZATION DATA BY CROSS-VALIDATION

PRM39  B14  INCLUSION OF LEARNING CURVE EFFECTS IN ECONOMIC EVALUATIONS OF MEDICAL DEVICES: EMPIRICAL EVIDENCE FOR HTA
Armeni P1, Federici C1, Costa F1, Tarricone R2, Torbica A2, Callea G2, SDA-Bocconi School of Management, Centre for Research in Healthcare Management (CERGAS), Milano, Italy, 2Bocconi University, Milan, Italy

PRM40  B15  IMPACT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) CODING DIFFERENCES ON HEALTH CARE UTILIZATION AND COST OUTCOMES FOR RESEARCH SPANNING THE ICD-9 TO ICD-10 TRANSITION
Bengtson LG1, McPheters JT1, Fang Y1, Cao F1, Elliott C1, Fox KM2, Biukema AR1, DePietro M3, Optum, Eden Prairie, MN, USA, 2AstraZeneca, Wilmington, DE, USA

PRM41  B16  PAYING FOR YEARS OF LIFE LOST: A PROPOSAL TO ESTIMATE TOBACCO TAXATION IN COLOMBIA
Gli-Tamayo S1, Rosselli D3,1Pontificia Universidad Javeriana, Bogota, Colombia, 2Pontificia Universidad Javeriana, Bogotá, Colombia

RESEARCH ON METHODS - Databases & Management Methods

PRM42  B17  COMPARISON OF THE CMS CHRONIC CONDITIONS DATA WAREHOUSE (CCW) ALGORITHMS AND THE CONDITION-BASED AND PRESCRIPTION-BASED COMORBIDITY SCORES AS PREDICTORS OF AMBULATORY HEALTHCARE UTILIZATION
Bhattacharya K1, Banahan III B2,1University of Mississippi, University, MS, USA, 2Center for Pharmaceutical Marketing and Management, University of Mississippi, University, MS, USA
PRM43 B18 PATIENT-LEVEL SIMULATION-BASED SENSITIVITY ANALYSIS TO EVALUATE THE IMPACT OF UNDER-RECORDING OF UNDERLYING COMORBIDITIES IN A RETROSPECTIVE CLAIMS DATABASE ANALYSIS
Zorina O1, Ferreira A1, Korn JR2, Bezlyak V1, Sagkriotis A1, Skelly A1, Zangvil E1, Snow H1, Zuurman L1, Holekamp N3, Novartis Pharma AG, Basel, Switzerland, 2IMS Health, Waltham, MA, USA, 3Pepose Vision Institute, Chesterfield, MO, USA

PRM44 B19 CORE CLINICAL DATA ELEMENTS FOR CANCER GENOMIC REPOSITORIES: A MULTI-STAKEHOLDER CONSENSUS
Conley RB1, Dickson DJ2, Zenklusen JC3, Al Naber J1, Messner DA1, 1Center for Medical Technology Policy, Baltimore, MD, USA, 2Molecular Evidence Development Consortium, Rexburg, ID, USA, 3National Cancer Institute, Bethesda, MD, USA

PRM45 B20 BIG DATA ANALYTICS FOR EARLY DIAGNOSIS OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Grabowsky T1, Shukla O1, Kasoji M1, Merrill C2, Agnese W2, Atassi N3, HVH Patient Precision Analytics, LLC, King of Prussia, PA, USA, 2MT Pharma America, Inc., Jersey City, NJ, USA, 3Neurological Clinical Research Institute (NCRI), Massachusetts General Hospital, Boston, MA, USA

PRM46 B21 SIMILARITIES AND DIFFERENCES BETWEEN REAL WORLD PATIENT DATA SOURCES: A GLOBAL CASE STUDY
Jaffe DH1, Haskell T2, Feldman B3, Bramlett J4, Bachrach A5, Hyunjung A6, Kamauu AW6, Friedel H7, Pignot M8, Kantar Health, Ramat-Gan, Israel, 2Kantar Health, Horsham, PA, USA, 3Clalit Health Services, Tel Aviv, Israel, 4Kantar Health, St Louis, MO, USA, 5Kantar Health Korea, Seoul, Korea, Republic of (South), 6Anolinx LLC, Salt Lake City, UT, USA, 7Team Gesundheit, Essen, Germany, 8Kantar Health, Munich, Germany

PRM47 B22 VALIDATION OF A WEIGHTED HEALTH STATE INDEX FOR DEPRESSED PATIENTS IN HEALTHCARE DATABASES: A SURVEY OF UK GENERAL PRACTITIONERS AND PSYCHIATRISTS
Touya M1, Wade AG2, Cloitre P3, Falissard B4, Lancer C5, Llorca PM6, Francois C7, Saragoussi D8, Lundbeck LLC, Deerfield, IL, USA, 2Patients Direct, Glasgow, UK, 3Lundbeck SAS, Issy-les-Moulineaux, France, 4INSERM UMR-S 1178 (Mental Health and Public Health), Paris, France, 5Marseille University Hospital, Marseille, France, 6CMP B CHU Clermont-Ferrand, Universtes d'auvergne EA 7280, Clermont-Ferrand, France, 7Lundbeck, LLC, Deerfield, IL, USA

PRM48 B23 USING REAL-WORLD DATA TO SUPPORT PROTOCOL OPTIMIZATION: A MULTI-COUNTRY APPROACH IN ULCERATIVE COLITIS
Brinkley E1, Midha Y2, Lobeck F1, Dreyer NA3, Lang K4, Christian JB1, 1QuintilesIMS, Durham, NC, USA, 2QuintilesIMS, Morisville, NC, USA, 3QuintilesIMS, Cambridge, MA, USA, 4QuintilesIMS, New York, NY, USA

PRM49 B24 CASE STUDIES ON THE IMPACT OF ICD-9-CM TO ICD-10-CM CODING TRANSITION ON STUDIES USING REAL-WORLD DATA IN THE UNITED STATES
Ali AK1, Beyrer JK1, Shroeder KM1, Wu J1, Haldane DC1, Mitchell L2, 1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and company, Erl Wood, UK

PRM50 C1 CHALLENGES OF IDENTIFYING TREATMENT PATTERNS OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA USING CLAIMS DATA IN THE UNITED STATES
Zhu YE1, Fang Y2, Nicol S1, Beyrer JK1, Hess LM1, 1Eli Lilly and Company, Indianapolis, IN, USA, 2inVentiv Health, Indianapolis, IN, USA

PRM51 C2 USABILITY EVALUATION OF CLINICAL AND OPERATIONAL POPULATION MANAGEMENT TOOLS IN VISN 21
Bena JM1, Taylor J1, Carmichael J1, Meier J2, Robinson A3, 1VA Sierra Pacific Network (VISN 21), Reno, NV, USA, 2VA Sierra Pacific Network (VISN 21), Martinez, CA, USA, 3VA Patient Education Resource Center, Palo Alto, CA, USA

PRM52 C3 DEVELOPMENT OF EPISODE-BASED PAYMENT MODELS FOR CHRONIC MYELOGENOUS LEUKEMIA (CML), LUNG CANCER, MELANOMA, AND BREAST CANCER
Kangethe A1, Poisson M1, Lord T1, Evangelatos T1, Speicher LC1, Barrientos S1, Zacker C2, 1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PRM53 C4 THE IMPACT OF CARE DISCONTINUITY ON RECORDING PATIENT CHARACTERISTICS CRITICAL FOR COMPARATIVE EFFECTIVENESS AND SAFETY RESEARCH WHEN USING ELECTRONIC HEALTH RECORDS
Lin KJ1, Glynn RJ1, Singer DE2, Schneeweiss S1, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, 2Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

PRM54 C5 INTEREST IN REAL-WORLD RESEARCH AMONG PHYSICIANS IN SMALL PRACTICE SETTINGS ACCESSED VIA AN ELECTRONIC MEDICAL RECORDS SYSTEM
THOMPSON D1, Levy D2,1inVentivHealth, Manchester, MA, USA, 2Amazing Charts, LLC, Boston, MA, USA

PHARMACEUTICAL STRATEGIC PRICING: AN ANALYSIS OF GLOBAL CROSS-SKU PRICING APPROACHES
Sogokon P1, Bustamante MM2, Park S2, Bastian A1, 1formerly CBPartners, London, UK, 2CBPartners, New York, NY, USA, 3INCYTE CORPORATION, Wilmington, DE, USA

THE VALUE OF REAL-WORLD DATABASES IN RARE DISEASES: UTILITY AND APPLICATIONS IN FABRY DISEASE
Avetisyan R, Greene N, Hamed A, Sanofi Genzyme, Cambridge, MA, USA

BRAZILIAN HEALTHCARE RECORD LINKAGE (BRHC-RLK) – A RECORD LINKAGE METHODOLOGY FOR BRAZILIAN MEDICAL CLAIMS DATASETS (DATASUS)
Campos DF1, Rosim RP2, Duva AS2, Ballalai Ferraz AF1, 1QuintilesIMS, São Paulo, Brazil, 2QuintilesIMS, Sao Paulo, Brazil

CLINICAL EFFICACY AND COST EFFICIENCY ASSESSMENT OF CADAVERIC ALLOGRAFT SKIN GRAFTING IN THE MANAGEMENT OF EXTENSIVE BURNS AND SEVERE WOUNDS
Sassykova A1, Gurtskaya G2, 1Republican Center for Health Development, Astana, Kazakhstan, 2Astana medical university, Astana, Kazakhstan

EVALUATING THE EFFECT OF PRESCRIPTION MONITORING PROGRAM CASH PRESCRIPTIONS ON THE PQA MEASURE: USE OF OPIOIDS FROM MULTIPLE PROVIDERS IN PERSONS WITHOUT CANCER
Ramachandran S1, Inguvu S2, Banahan III B2, Noble S3, Kirby T3, 1University of Mississippi, University, MS, USA, 2Center for Pharmaceutical Marketing and Management, University of Mississippi, University, MS, USA, 3Office of the Governor, Mississippi Division of Medicaid, Jackson, MS, USA

MACHINE LEARNING INTEGRATION WITH MOLECULAR DIAGNOSTICS: PROGRESS AND POTENTIAL PITFALLS
Ringo M, Faulkner E, Evidera, Raleigh, NC, USA

CREATING A LARGE-SCALE PHYSICALLY INTEGRATED ELECTRONIC HEALTH RECORD DATA SYSTEM TO SUPPORT A LEARNING HEALTHCARE SYSTEM
Dore DD1, Ciofani D2, Davis S3, Nunes AP1, Bradley JM1, Seeger JD3, Berger M4, 1Optum, Boston, MA, USA, 2Optum-Humedica, Boston, MA, USA, 3Optum, Waltham, MA, USA, 4Pfizer, Inc., New York, NY, USA

A FITRADEOFF APPROACH FOR ASSESSMENT AND UNDERSTANDING OF PATIENT ADHERENCE BEHAVIOR
Shukla S1, IIM Lucknow, Lucknow, India

USING PROPENSITY MATCHING AND IMPUTATION METHODS TO INTEGRATE PATIENT-REPORTED SURVEY DATA WITH ELECTRONIC HEALTH RECORDS IN TYPE 2 DIABETES
Lee LK1, Liebert R2, Gupta S2, Flores NM1, Haskell T3, 1Kantar Health, San Mateo, CA, USA, 2Kantar Health, New York, NY, USA, 3Kantar Health, Horsham, PA, USA

EARLY ANALYSES OF NEWLY APPROVED DRUGS MAY PRODUCE BIASED CONCLUSIONS
Hess LM1, Grabner M2, Wang L3, Liepa A1, Cui ZL2, Schelman W1, Bowman L1, 1Eli Lilly and Company, Indianapolis, IN, USA, 2HealthCore Inc, Wilmington, DE, USA, 3HealthCore Inc., Wilmington, DE, USA

RESEARCH ON METHODS - Modeling Methods

USING RANDOM FOREST FOR RISK PREDICTION MODEL OF HOSPITALIZATION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Nguyen T1, Carlson AM2, Heins-Nesvold J3, 1University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence Consultants, LLC, Eden Prairie, MN, USA, 3American Lung Association of the Upper Midwest, St. Paul, MN, USA

META-ANALYZING TIME-SPECIFIC EVENTS USING COMPOUND POISSON PROCESS: THE CASE FOR POST-STROKE SEIZURES
Wang W, Devine B, Basu A, University of Washington, Seattle, WA, USA

AN ACTIVE LEARNING ALGORITHM FOR EFFICIENT DEVELOPMENT OF EMULATORS OF COMPLEX MODELS, WITH AN APPLICATION IN PROSTATE CANCER SCREENING
Ellis AG1, Trikalinos TA, Brown University, Providence, RI, USA

VALIDATION OF A TYPE 2 DIABETES MONTE CARLO MICRO-SIMULATION MODEL USING REAL-WORLD DATA
Murphy DR1, Saundankar V2, Perk S1, Nair R2, Yu X1, Curtis BH3, Tzeel A1, 1Medical Decision Modeling Inc., Indianapolis, IN, USA, 2Comprehensive Health Insights, Louisville, KY, USA, 3Eli Lilly and Company, Sydney, Australia, 4Humana Inc, Jacksonville, FL, USA
PRM69 C20 APPROACHES TO STANDARDISING CARDIOVASCULAR RISK EQUATION ENDPOINTS IN ORDER TO FACILITATE THEIR INCLUSION WITHIN A TYPE 2 DIABETES MODEL
McEwan P1, Foos V2, Lamotte M3, Health Economics and Outcomes Research Ltd, Cardiff, UK, 2IMS Health, Zaventem, Belgium

PRM70 C21 CAN IRELAND’S COLORECTAL SCREENING PROGRAMME SAVE MORE LIVES, SAVE MONEY AND LIVE WITHIN EXISTING COLONOSCOPY CAPACITY LIMITS? FINDINGS FROM THE MISCAN MICROSIMULATION MODEL
McFerran E1, O’Mahony JF2, 1Queen’s University Belfast, BELFAST, UK, 2Trinity College Dublin, Dublin, Ireland

PRM71 C22 DEVELOPMENT OF A DEPENDENCE SCALE-BASED COST-EFFECTIVENESS FRAMEWORK TO ASSESS THE VALUE OF ALZHEIMER’S DISEASE TREATMENTS
Roth JA1, Cohen JT2, Neumann PJ3, Zhu CW4, Stern Y4, Sullivan SD5, 1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2Tufts Medical Center, Boston, MA, USA, 3Icahn School of Medicine at Mount Sinai, Bronx, NY, USA, 4Columbia University, New York, NY, USA, 5University of Washington, Seattle, WA, USA

PRM72 C23 COMPARISON OF COST-EFFECTIVENESS ACCEPTABILITY CURVES (CEAC) IN MODELED ANALYSES WITH AND WITHOUT ESTABLISHED HETEROGENEITY OF PATIENT CHARACTERISTICS
Foos V1, McEwan P2, Lamotte M1, 1IMS Health, Zaventem, Belgium, 2Health Economics and Outcomes Research Ltd, Cardiff, UK

PRM73 C24 PREDICTION OF HYPOGLYCEMIA RISK AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) USING AN ENSEMBLE-BASED, HYPOTHESIS-FREE PROCEDURE
Thai N1, Wei LJ2, Alas V1, Khalil I1, Berhanu P3, Dalal MR4, Sung J3, 1GNS Healthcare, Cambridge, MA, USA, 2Harvard School of Public Health, Boston, MA, USA, 3Sanofi U.S., Inc., Bridgewater, NJ, USA, 4Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company limited, Cambridge, MA, USA

PRM74 D1 EFFECT OF DURATION OF FOLLOW-UP ON CALCULATING MULTIPLE MYELOMA TREATMENT PROBABILITIES USING INCIDENCE DENSITY RATIOS
Kozma CM1, Slaton T1, Maiese EM1, 1CK Consulting Associates, LLC, Saint Helena Island, SC, USA, 2Janssen Scientific Affairs, LLC, Horsham, PA, USA

PRM75 D2 USE OF RELATIVE RISK RATIOS TO PRESENT UNCERTAINTY IN MICROSIMULATION MODELS WITH MULTIPLE COMPARATORS: AN APPLICATION TO BREAST CANCER SCREENING STRATEGIES
Shih YT, Doug W, Xu Y, Yu S, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

PRM76 D3 PREDICTING THE RISK OF DIABETIC RETINOPATHY USING ARTIFICIAL NEURAL NETWORK AND BIG DATA IN HEALTHCARE
Wang B1, Shi R2, 1Ivy Analytics LLC, Garnet Valley, PA, USA, 2Kang Chiao International School, Shanghai, China

PRM77 D4 FORECASTING DRUG DIFFUSION IN THE US COMMERCIAL INSURANCE MARKET
Rosen MM, 1University of Washington, Seattle, WA, USA

PRM78 D5 NON-PROPORTIONAL HAZARDS. EXTRAPOLATING RELATIVE TREATMENT EFFECTS BEYOND OBSERVED DATA WITH CANCER IMMUNOTHERAPIES
Bryden P, Paracha N, Gsteiger S.F. Hoffman-La Roche, Basel, Switzerland

PRM79 D9 EVIDENCE SYNTHESIS FOR DIAGNOSTIC TESTS WITH PARTIALLY ORDERED PERFORMANCE AND NO REFERENCE TEST
Forbes SP1, Di M1, Salomon J2, Linas BP3, Trikalinos TA1, 1Brown University, Providence, RI, USA, 2Harvard University, Boston, MA, USA, 3Boston Medical Center, Boston, MA, USA

PRM80 D7 MODELING THE IMPACT OF EXOGENOUS BOOSTING ON HERPES ZOSTER: AN UPDATED METHODOLOGICAL REVIEW OF THE VARICELLA ZOSTER VIRUS LITERATURE
Talbird SE1, La EM1, Mauskopf J1, Krueger WS1, Altland A2, Daniels VJ3, Pillsbury M2, Wolfson Lj1, 1RTI Health Solutions, Research Triangle Park, NC, USA, 2Merck & Co., Inc., Kenilworth, NJ, USA, 3Merck & Co. Inc., Kenilworth, NJ, USA

PRM81 D8 ESTIMATION OF INJECTABLE DRUG STRENGTH FROM INSURANCE CLAIMS DATABASE

PRM82 D9 ESTIMATING THE IMPACT OF CHANNELING BIAS ON REAL-WORLD SURVIVAL IN ADVANCED CANCER
Wiecek W1, Amzal B2, Casciano R3, Karcher H1, LASER Analytica, London, UK, 2LASER ANALYTICA, London, UK, 3LASER Analytica, New York, NY, USA
A CRITICAL APPRAISAL OF THE USE OF MARKOV MODELLING APPROACHES IN ECONOMIC MODELS OF ANXIETY

Olariu E, Mbanya Z, Fox D, Ratcliffe M, Longworth L, PHMR Ltd, London, UK

HERPES ZOSTER VACCINE EFFECTIVENESS AND WANING OF EFFECTIVENESS

Johnson KD, Jiang Y, Weiss T, Graham J, Merck & Co., Inc., Kenilworth, NJ, USA, 2Merck Sharp & Dohme Limited, Hoddesdon, UK, 3RTI Health Solutions, Durham, NC, USA

USE OF MUTUAL INFORMATION THEORY IN BUILDING A PREDICTIVE MODEL FOR ANKYLOSING SPONDYLITIS DIAGNOSIS

Garges C, Shukla O, DeFreitas F, Grabowsky T, Park Y, Deodhar A, HVH Precision Analytics, King of Prussia, PA, USA, 2HVH Patient Precision Analytics, LLC, King of Prussia, PA, USA, 3Novartis Pharmaceuticals, East Hanover, NJ, USA, 4Oregon Health & Science University, Portland, OR, USA

RATIONAL COMPUTER ASSISTED DESIGN FOR THE STUDY OF ACUTE TOXICITY OF LOCAL ANESTHETICS

Amirkulova M, Seitaliyeva A, Satbayeva E, Ananyeva L, Tilekeeva U, 1Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan, 2Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan

EXPLORING PYTHON FOR USE IN MODELING: DECREASING RUN-TIMES FOR PROBABILISTIC SENSITIVITY ANALYSIS

Stokes ME, Quon P, 1Evidera, St-Laurent, QC, Canada, 2Evidera, Bethesda, MD, USA

HEALTH STATES UTILITY VALUES IN NICE MULTIPLE TECHNOLOGY APPRAISALS: ADHERENCE TO THE NICE REFERENCE CASE IN THE AREA OF CANCER

Lucherini S, Mujica-Mota RE, Medina-Lara A, University of Exeter, Exeter, UK

MODELING WITH VERY BIG DATA: A PILOT STUDY USING LARGE-SCALE MACHINE LEARNING IN A CLUSTER COMPUTING FRAMEWORK TO PREDICT EMERGENCY ROOM (ER) VISITS

Xu Y, Yao W, Dusenberry MW, Pohlman M, 1IBM, Cleveland, OH, USA, 2IBM, San Francisco, CA, USA

THE PATIENT VOICE INCLUDES EMOJIS: A CASE STUDY IN THE USE OF PROBABILISTIC TOPIC MODELING TO CHARACTERIZE PATIENT CONVERSATIONS IN AN ONLINE COMMUNITY OF PTSD PATIENTS

Eaneff SD, PatientsLikeMe, Cambridge, MA, USA

LONSTIDUAL DETERMINANTS OF DYNAMIC STATIN ADHERENCE: A RETROSPECTIVE COHORT STUDY

Dave C, Park H, Winterstein A, Hartzema A, University of Florida, Gainesville, FL, USA

ASSESSMENT OF PROPORTIONAL HAZARDS IN NICE SUBMISSIONS: A REVIEW OF RECENT NICE APPRAISALS IN CANCER

Padhiar A, Quigley JM, Ward K, Callen H, Scott DA, ICON Health Economics & Epidemiology, Abingdon, UK

WHEN DOUBLY ROBUST IS NOT ROBUST ENOUGH: NONPARAMETRIC MATCHING METHODS UNDER TREATMENT HETEROGENEITY

Shao H, Stoecker C, Shi L, Tulane University School of Public Health and Tropical Medicine, NEW ORLEANS, LA, USA

SIMULATING MULTIVARIATE DISTRIBUTIONS WITH ARBITRARY MARGINAL DISTRIBUTIONS AND DEPENDENCE STRUCTURES

Iskandar R, Trikalinos TA, Brown University, Providence, RI, USA

EVALUATING THREE MARKOV MATRIX SOFTWARE MODELS FOR HIV TREATMENT COST EFFECTIVENESS ANALYSIS

Chaudhari V, Parmar A, Maniar A, McGhan WF, University of the Sciences, Philadelphia, PA, USA

WHY ISN'T IT THE NORM TO USE NORMAL IN PSA?

Oguz M, Roiz J, Evidera, London, UK
PRM99  E2  BAYESIAN ANALYSIS OF FLEXIBLE PARAMETRIC FRAILTY MODELS FOR THE EVALUATION OF REPEAT TREATMENT IN PATIENTS WITH INTERVAL CENSORED DATA: APPLICATION TO A LARGE RANDOMISED CONTROLLED TRIAL IN OVERACTIVE BLADDER SYNDROME
Owen RK, Tincello DG, Abrams KR, University of Leicester, Leicester, UK

PRM100  E3  MODELING MIGRAINE DAY FREQUENCY USING THE BETA-BINOMIAL DISTRIBUTION: A CASE STUDY OF ERENUMAB AS MIGRAINE PROPHYLAXIS
Porter JK1, Brennan A2, Palmer S3, Sapra S4, Shah N4, Desai P4, Villa G1, Lipton RB5,1 Amgen (Europe) GmbH, Zug, Switzerland, 2University of Sheffield, Sheffield, UK, 3University of York, Heslington, York, UK, 4Amgen Inc, Thousand Oaks, CA, USA, 5Albert Einstein College of Medicine, Bronx, NY, USA

PRM101  E4  PERFORMANCE OF MACHINE LEARNING ALGORITHMS IN PREDICTING 30 DAY HEART FAILURE READMISSIONS RISK USING AN ADMINISTRATIVE CLAIMS DATABASE
Dave C, Park H, Hartzema A, University of Florida, Gainesville, FL, USA

PRM102  E5  CALIBRATION OF DISEASE MODELS FOR HEALTH SYSTEMS EVALUATION
Semochkina D1, Walsh C1, White A2, University of Limerick, Limerick, Ireland, 2Trinity College Dublin, Dublin, Ireland

PRM103  E6  MODELING LONGITUDINAL CHANGE IN PATIENT REPORTED OUTCOMES USING LATENT CURVE MODELS
McGinley JS, Wirth R, Vector Psychometric Group, LLC, Chapel Hill, NC, USA

PRM104  E7  HOPE, “HEALTH OUTCOMES PERFORMANCE ESTIMATOR”: A NEW TOOL TO PREDICT REAL-LIFE OUTCOMES

PRM105  E8  VALIDATION OF HOSPITAL MANAGEMENT EVALUATING METHODS IN CHINA
Cui Y1, Zhao H2, Liu GG1, He Y2, Yang M2, Wang M2, National School of Development, Peking University, Beijing, China, 2China Center for Health Economic Research, Peking University, Beijing, China

PRM106  E9  A META-EPIDEMIOLOGICAL SURVEY OF THE REPORTING OF EFFECT MODIFICATION IN NETWORK META-ANALYSES.
Kovic B1, Zoratti M1, Michalopoulos S2, Silvestre C2, Thorlund K1, Thabane L1, McMaster University, Hamilton, ON, Canada, 2Precision Health Economics, Vancouver, BC, Canada, 3University of Waterloo, Milton, ON, Canada

RESEARCH ON METHODS - Patient-Reported Outcomes Studies

PRM107  E10  STATISTICAL MAPPING OF UTILITY SCORES FROM THE REVISED FIBROMYALGIA IMPACT QUESTIONNAIRE
AlAujan S1, Elliott RA2, Knaggs RD1, Luciano JV3,1 University of Nottingham, Nottingham, UK, 2Manchester Centre for Health Economics, Manchester, UK, 3Parc Sanitari Sant Joan de Déu, Barcelona, Spain

PRM108  E11  MEASUREMENT PROPERTIES OF THE RASCH-BUILT OVERALL DISABILITY SCALE IN PATIENTS WITH HEREDITARY ATTR AMYLOIDOSIS WITH POLYNEUROPATHY
Regnault A1, Denoncourt RN2, Strahs A2, Agarwal S2, Marquis P3, Cano S1, Modus Outcomes, Lyon, France, 2Alnylam Pharmaceuticals, Cambridge, MA, USA, 3Modus Outcomes, Newton, MA, USA, 4Modus Outcomes, Stotfold, UK

PRM110  E12  AN EVALUATION OF THE PSYCHOMETRIC PROPERTIES OF THE SF-12V2 HEALTH SURVEY AMONG ADULTS WITH HEMOPHILIA IN THE UNITED STATES.
Shah R1, Bentley JP2, Banahan III B3, Holmes E2, Patel A4, Khanna R5, Barnard M2,1 Pharmerit International, Bethesda, MD, USA, 2University of Mississippi, University, MS, USA, 3Center for Pharmaceutical Marketing and Management, University of Mississippi, University, MS, USA, 4Medical Marketing Economics, Oxford, MS, USA, 5Johnson & Johnson, New Brunswick, NJ, USA

PRM111  E13  QUALITATIVE RESEARCH TO EXPLORE THE PATIENT EXPERIENCE OF X-LINKED HYPOPHOSPHATASAEMIA (XLH) AND TO EVALUATE THE CONTENT VALIDITY OF THE BPI-SF AND WOMAC® FOR USE AS CLINICAL TRIAL ENDPOINTS
Theodore-Oklota C1, Arbuckle R2, Bonner N2, Spencer H2, Ultragenyx, Brisbane, CA, USA, 2Adelphi Values Ltd, Bollington, UK

PRM112  E14  CONTENT VALIDITY OF QUESTIONNAIRES ASSESSING INJECTION REGIMEN BURDEN IN GROWTH HORMONE DEFICIENT (GHD) ADULTS AND CHILDREN TREATED WITH GROWTH HORMONE
Turner-Bowker DM1, Shields A1, Yaworksys A1, Lamoureux RE1, Morrissey L1, Kelly M1, Love E1, Pleil A2, Hart G2, Hershkovitz O2, Loftus J1, Adelphi Values, Boston, MA, USA, 2Pfizer, Inc, San Diego, CA, USA, 3OPKO Biologics, Ness Ziona, Israel, 4Pfizer Ltd, Tadworth, UK
PRM113 E15 PREDICTORS OF UTILITY OVER TIME AMONG PATIENTS WITH TREATMENT-NAIVE ADVANCED MELANOMA FROM THE PHASE 3 CHECKMATE 067 TRIAL: 28-MONTH UPDATE

Paly VF1, Colby C2, Sabater J3, Kotapati S4, ICON Health Economics & Epidemiology, Morristown, NJ, USA, 2ICHS Health Economics & Epidemiology, San Francisco, CA, USA, 3Bristol-Myers Squibb, Princeton, NJ, USA

PRM114 E16 EQ-5D-3L UTILITIES TARIFFS: DIFFERENCES IN GERMAN AND UK UTILITIES AND QALYS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

Sherif B1, Graham CN1, Neidhardt K2, Gilloteau J3, O'Neil CB4, McBride D5, Augustin M6, 1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma GmbH, Nuernberg, Germany, 3Novartis Pharma AG, Basel, Switzerland, 4Novartis Ireland Ltd, Elm Park, Ireland, 5RTI Health Solutions, Manchester, UK, 6University Clinics of Hamburg, Hamburg, Germany

PRM115 E17 ARE PATIENT'S RESPONSES TO FIVE POINT VERBAL DESCRIPTOR SCALES AND VISUAL ANALOGUE SCALES REPPLICATE MEASURES? AN EXPERIMENTAL MANIPULATION

Evans C1, Serrano D1, Witherspoon B1, Khurana L2, Dallabrida SM2, 1Endpoint Outcomes, Boston, MA, USA, 2ERT, Boston, MA, USA

PRM116 E18 MODE COMPARISON IN ELICITING PREFERENCES FOR CARE-RELATED QUALITY OF LIFE: EVIDENCE FROM ENGLAND USING THE ASCOT SERVICE USER MEASURE

Saloniki E1, Batchelder L1, Malley J2, Burge P3, Lu H4, Forder J5, 1University of Kent, Canterbury, UK, 2London School of Economics and Political Science, London, UK, 3RAND Europe, Cambridge, UK

PRM117 E19 PSYCHOMETRIC VALIDATION OF THE ATOPIC DERMATITIS IMPACT QUESTIONNAIRE (ADIQ)

Boruvka A1, Curry C2, Lin C3, Omachi TA4, Olsson J5, DeBusk K6, 1Roche, Mississauga, ON, Canada, 2Genentech, South San Francisco, CA, USA

PRM118 E20 A SYSTEMATIC REVIEW OF QUALITY OF LIFE DOMAINS AND ITEMS RELEVANT TO PATIENTS WITH SPONDYLOARTHITIS

Kwan YH1, Fong W2, Tan V3, Lui NL4, Malhotra R1, Ostbye T5, Thumboo J6, 1Duke-NUS Medical School, Singapore, 2Singapore General Hospital, Singapore, Singapore

PRM119 E21 LINGUISTIC VALIDATION OF THE NEUROGENIC BOWEL DYSFUNCTION SCORE IN JAPANESE

Crane AL1, Gallo Santacruz B2, Popielnicki A3, Sweeney E1, Sørensen J2, 1University of Kent, Canterbury, UK, 2Coloplast A/S, Humlebaek, Denmark, 3TransPerfect, Boston, MA, USA

PRM120 E22 DERIVING MAPPED HEALTH STATE UTILITY VALUES FOR ECONOMIC EVALUATION USING SUMMARY HEALTH RELATED QUALITY OF LIFE MEASURES AS SUFFICIENT STATISTICS

Mujica-Mota RE1, Medina-Lara A, 1University of Exeter, Exeter, UK

PRM121 E23 PSYCHOMETRIC EVALUATION OF THE BRIEF PAIN INVENTORY - SHORT FORM (BPI-SF) AND WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX (WOMAC®) FOR USE IN X-LINKED HYPOPHOSPHATAEMIA (XLH), A RARE GENETIC DISORDER

Theodore-Okloza C1, Brohan E2, Marshall C3, Tritton T3, 1Ultragenyx, Brisbane, CA, USA, 2Adelphi Values Ltd, Bollington, UK

PRM122 E24 HOW WELL DOES THE EQ-5D-5L SCREEN FOR MENTAL HEALTH COMPARED TO THE SF-12?

Al Sayah F1, Ohinmaa A, Johnson J2, School of Public Health, University of Alberta, Edmonton, AB, Canada

PRM123 E25 A TALE OF TWO SURVEYS: PATIENT SURVEY RECRUITMENT VIA EMAILS AND LETTERS

Stephenson JJ1, Marshall AR, Dinh J, Merkh RD, Paullin M, HealthCore Inc., Wilmington, DE, USA

PRM124 E26 ADAPTING THE MEDICATION ADHERENCE REASONS SCALE (MAR-SCALE) FOR ONLINE ADMINISTRATION ACROSS MULTIPLE COMORBID CONDITIONS, MODES OF ADMINISTRATION, AND FREQUENCIES OF USE

Goren A1, Annunziata K1, Unni E2, 1Kantar Health, New York, NY, USA, 2University of Technology Sydney, Sydney, Australia, 3Curtin University, Perth, Australia

PRM125 F1 INVESTIGATING THE RELATIVE VALUE OF HEALTH AND SOCIAL CARE RELATED QUALITY OF LIFE USING DISCRETE CHOICE

Mulhern B1, Norman R2, DeAbreu Lourenco R1, Viney R1, 1University of Technology Sydney, Sydney, Australia, 2Curtin University, Perth, Australia

PRM126 F2 PAIN ASSESSMENT: A MYRIAD OF TECHNIQUES TO MEASURE PAIN SEVERITY – DOES IT MATTER WHICH ONE IS USED?

Evans C1, Serrano D1, Witherspoon B1, Khurana L2, Dallabrida SM2, 1Endpoint Outcomes, Boston, MA, USA, 2ERT, Boston, MA, USA
PRM127 F3 COMPARING HEALTH-RELATED QUALITY OF LIFE OF SCHIZOPHRENIC PATIENTS WITH PREDOMINANT NEGATIVE SYMPTOMS TREATED WITH CARIPRAZINE AND RISPERIDONE

Nemeth B1, Molnar A1, Horvath M2, Koczian K2, Nemeth G2, Gotze A2, Voko Z1, Syreon Research Institute, Budapest, Hungary, 2Gedeon Richter Plc., Budapest, Hungary, 3Ezötvös Loránd University, Budapest, Hungary

PRM128 F4 IS THE SF-6D DAILY SENSITIVE TO CAPTURE QALY-VARIATION ON REACTOGENICITY OF INJECTABLE VACCINES?

Meier C1, Kosinski M2, Dort T3, Madan A4, Standaert B5, Schuind A4,1Eisai, Woodcliff Lake, NJ, USA, 2Optum, Lincoln, RI, USA, 3Keyrus Management S.A. on behalf of GSK Vaccines, Stroombeek-Bever, Belgium, 4GSK Vaccines, Collegeville, PA, USA, 5GSK Vaccines, Wavre, Belgium

PRM129 F5 LET THERE BE LITE

Kind P1, Chuang L2,1Institute of Health Sciences, University of Leeds, Leeds, UK, 2Pharmerit International, Rotterdam, The Netherlands

PRM130 F6 EQUIVALENCE OF TELEPHONE AND FACE-TO-FACE PATIENT-REPORTED OUTCOME INTERVIEWS: LITERATURE REVIEW AND IMPLICATIONS FOR THE NEI VFQ-25

Kapre A1, Tschosik E1, Silverman D2, Dolan C3, Varma R4, Bressler N5,1Genentech, Inc., South San Francisco, CA, USA, 2Roche Products Limited, Welwyn Garden City, UK, 3CMD Consulting, Inc., Sandy, UT, USA, 4USC Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, 5Johns Hopkins University School of Medicine, Baltimore, MD, USA

PRM131 F7 TRANSLATION OF THE ZARIT BURDEN INTERVIEW 22 ITEMS (ZBI-22) INTO 95 LANGUAGES: CHALLENGES AND IMPORTANCE OF THE CONCEPTUAL DEFINITION OF THE ORIGINAL VERSION

Zarit S1, Dulac M2, Anfay C3, Varasri S4, Giroudet C5,1Pennsylvania State University, University Park, PA, USA, 2Mapi Research Trust, Lyon, France, 3Mapi, Yardley, PA, USA, 4Mapi, Lyon, France

PRM132 F8 LINGUISTIC VALIDITY OF AN INSTRUMENT TO EVALUATE HEALTH-RELATED QUALITY OF LIFE IN PEDIATRIC PATIENTS WITH GROWTH HORMONE INSUFFICIENCY IN 7 LANGUAGES FOR 5 COUNTRIES

Brandt B1, Yohe Moore E2, Jacobs K3, Poepsel T4,1Corporate Translations Inc, East Hartford, CT, USA, 2Corporate Translations Inc Chicago, IL, USA

PRM133 F9 ADAPTATION AND ASSESSMENTS OF THE CHINESE VERSION OF THE ICECAP-A MEASUREMENT

Xu J1, Tang C1, Xiong Y1, Wu H2,1Southwestern University of Finance and Economics, Chengdu, China, 2Guizhou Medical University, Guizhou, China

PRM134 F10 THE NECESSITY OF A VISUAL CONCEPT ELABORATION WHEN TRANSLATING STANDARD ANATOMICAL TERMS FOR CLINICAL OUTCOMES ASSESSMENTS (COAS) IN NON-LATIN LANGUAGES

Richards A1, Mead H,1ICON Plc, Abingdon, UK

PRM135 F11 CONTENT VALIDITY OF THE PRESCRIPTION OPIOID MISUSE AND ABUSE QUESTIONNAIRE (POMAQ) AMONG CHRONIC PAIN PATIENTS

Coyne KS1, Barsdorf A2, Brooks A1, Mazière J3, Pierson RF4, Butler SF5, Schnoll S1, Evidera, Bethesda, MD, USA, 2Pfizer, Inc, New York, NY, USA, 3PPD, Wilmington, NC, USA, 4Janssen Global Services, LLC, Raritan, NJ, USA, 5Inflexion Inc., Waltham, MA, USA, 6Pinney Associates, Bethesda, MD, USA

PRM136 F12 COGNITIVE DEBRIEFING OF THE ADVANCED SYSTEMIC MASTOCYTOSIS SYMPTOM ASSESSMENT FORM (ADVSM-SAF)

Taylor F1, Kreil S2, Reiter A2, Horny H3, Evans E4, Mazar I1, Mcnamara P4, Boral A4, Lamoureux RE1, Shields A1, Gotlib J5,1Adelphi Values, Boston, MA, USA, 2University Hospital Mannheim, Mannheim, Germany, 3Ludwig-Maximilians University, München, Germany, 4Blueprint Medicines, Cambridge, MA, USA, 5Stanford Cancer Center, Standord, CA, USA

PRM137 F13 CHALLENGES IN TRANSLATING THE NEUROPSYCHIATRIC INVENTORY (NPI) INTO 74 LANGUAGES

Cummings J1, Giroudet C1, Dulac M2, Anfay C3, Varasri S4,1Reed Neurological Research Center, Los Angeles, CA, USA, 2Mapi, Lyon, France, 3Mapi Research Trust, Lyon, France, 4Mapi, Yardley, PA, USA

PRM138 F14 SATURATION OF SIGN AND SYMPTOM CONCEPTS IN CONCEPT ELICITION STUDIES WITH RARE DISEASE AND VULNERABLE PATIENT POPULATIONS

Mazar I, Shields A, Stokes J, Adelphi Values, Boston, MA, USA

PRM139 F15 SLEEP TRACKING AND EXERCISE IN DIABETES PATIENTS (STEP-D): A PILOT STUDY TESTING THE CONCURRENT VALIDITY OF FITBIT HR DATA WITH SELF-REPORT DATA

Weatherall J1, Paprocki Y1, Kudel I2, Meyer T3, Witt EA3,1Novo Nordisk Inc., Plainsboro, NJ, USA, 2Kantar Health, New York, NY, USA, 3Kantar Health, Princeton, NJ, USA
RESEARCH ON METHODS

PRM140 F16 IMPACT OF THE AGE OF THE TARGET AUDIENCE ON TRANSLATION DECISIONS
Volkmann CG, Windridge A, ICON Plc, Abingdon, UK

PRM141 F17 A HEARING BOLT-ON ITEM CAN INCREASE THE SENSITIVITY OF THE EQ-5D-5L INDEX SCORE TO HEARING IMPAIRMENT
Luo N1, Wang P2, Chong SL3,1 National University of Singapore, Singapore, Singapore, 2 Fudan University, Shanghai, China, 3 National University Hospital, Singapore, Singapore

PRM142 F18 LINGUISTIC VALIDATION OF THE RESPIRATORY Syncytial VIRUS NETWORK (RESVINET) PARENT AND CLINICIAN-FACING QUESTIONNAIRES IN ENGLISH AND SPANISH FOR THE UNITED STATES
King KM, Towns L, ICON Plc, Abingdon, UK

PRM143 F19 “AM I BOTHERED?” INVESTIGATING THE POTENTIAL PROBLEMS WITH THE WORD “BOther” IN THE LINGUISTIC VALIDATION OF QUALITY OF LIFE QUESTIONNAIRES.
Oke L, ICON Plc, Abingdon, UK

PRM144 F20 PLACEMENT OF RECALL PERIOD IN PATIENT-REPORTED OUTCOME QUESTIONNAIRE ITEMS: DOES IT MATTER?
Mazar I1, Taylor F1, Higgins S1, Shields AL1, Carson RT2, Eremenco S3, Reasner DS4, Levy-Hacham O5, Mizrahi R5, Milbauer M6, Nov O7, Toledano O2, Coons SJ1, Adelphi Valutes, Boston, MA, USA, 2Allergan plc, Jersey City, NJ, USA, 3Critical Path Institute, Tucson, AZ, USA, 4Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA, 5Sol Gel Technologies, Ness Ziona, Israel

PRM145 F21 PREVELANCE OF CVD AMONG TYPE 2 DM PATIENTS
Moodaresahmadi S, Al-Ameen College of Pharmacy, Bangalore, India

PRM146 F22 AN ALTERNATIVE WEIGHT ELICITATION METHOD FOR USE IN MULTI-CRITERIA DECISION ANALYSIS FOR HEALTHCARE
Diaby V1, Sanogo V2, Moussa RK3, Florida A & M University, Tallahassee, FL, USA, 2Florida State University, Tallahassee, FL, USA, 3Cergy-Pontoise University, Cergy-Pontoise, France

PRM147 F23 AN INNOVATIVE APPROACH TO MIXED-MODE LONGITUDINAL DATA COLLECTION: METHODS AND RESPONSE RATES FROM THE CHRONIC CONSTIPATION & IBS-C TREATMENT AND OUTCOMES REAL WORLD RESEARCH PLATFORM (CONTOR)
Essoi B1, Taylor DC2, Abel JL3, Carson RT3, Goolsby Hunter A1, Buzinec P1, Martin C1, Optum, Eden Prairie, MN, USA, 2Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA, 3Allergan plc, Jersey City, NJ, USA

PRM148 F24 VALIDATING SELF-REPORTED PATIENT SURVEY DATA ON DIABETES SELF-MANAGEMENT USING PATIENT ELECTRONIC MEDICAL RECORDS
Khaimar R1, Kamal KM2, McConaha J2, Giannetti V2, Dwibedi N3, University of Maryland, Baltimore, MD, USA, 2Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA, 3West Virginia University, School of Pharmacy, Morgantown, WV, USA

PRM149 F25 RECRUITEMENT STRATEGIES AND GEOGRAPHIC REPRESENTATIVENESS FOR PATIENT SURVEYS IN RARE DISEASES
Yu J, Paranaganama D, Parasaruman S, Incyte, Wilmington, DE, USA

RESEARCH ON METHODS - Statistical Methods

PRM150 F26 USING AGGREGATE DATA TO PROXY INDIVIDUAL-LEVEL CHARACTERISTICS IN HEALTH SERVICES RESEARCH: THE IMPACT OF GRANULARITY
Kilgore K, McClellan M, Tao VQ, Teigland C, Avalere Health - An Inovalon Company, Bowie, MD, USA

PRM151 G1 MATCHING-ADJUSTED INDIRECT COMPARISONS IN ANKYLOSING SPONDYLITIS, PSORIATIC-ARTHRITIS AND PSORIASIS: HOW DO THEY ALIGN WITH NICE DSU RECOMMENDATIONS?
Thom H1, Jurgi SM2, Gilloteau I2, Hawkins N3, University of Bristol, Bristol, UK, 2Novartis Pharma AG, Basel, Switzerland, 3University of Glasgow, Glasgow, UK

PRM152 G2 IRT IN ACTION: A DEMONSTRATION OF THE EQUIVALENCE OF IRT-BASED SCORING WHEN USING ITEM SUBSETS
Houts CR, Wirth R, Vector Psychometric Group, LLC, Chapel Hill, NC, USA

PRM153 G3 STATISTICAL EFFICIENCY AND BIAS OF DIFFERENCE IN DIFFERENCE DESIGN VERSUS NON-EQUIVALENT CONTROL GROUP ANALYSIS METHODS
Wasser T, HealthCore Inc., Wilmington, DE, USA

PRM154 G4 USING LATENT CLASS ANALYSIS TO MODEL PREFERENCE HETEROGENEITY IN HEALTH: A SYSTEMATIC REVIEW
Zhou M, Thayer WM, Bridges JF, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

PRM155 G5 SELECTING THE BEST PERFORMING METHODS TO CONTROL FOR BIAS IN COMPARATIVE EFFECTIVENESS RESEARCH USING REAL WORLD DATA
Parks DC1, Alfonso R2, Gutierrez B3, GSK, Phoenixville, PA, USA, 2GSK, Collgeville, PA, USA, 3GSK, 1250 S. collgeville Road, PA, USA

PRM157 G6 TWO-STAGE PIECEWISE LINEAR MODEL FOR INVESTING DOSE-RESPONSE RELATIONSHIP IN META-ANALYSIS: METHODOLOGY, EXAMPLES, AND COMPARISON
Chang X, Chinese Evidence-based medicine Center, Chengdu, China

PRM158 G7 POPULATION-ADJUSTED TREATMENT COMPARISONS: ESTIMATES BASED ON MAIC (MATCHING-ADJUSTED INDIRECT COMPARISONS) AND STC (SIMULATED TREATMENT COMPARISONS)
Phillippo DM1, Ades A1, Dias S1, Palmer S2, Abrams KR3, Welton NJ1, 1University of Bristol, Bristol, UK, 2University of York, Heslington, York, UK, 3University of Leicester, Leicester, UK

PRM159 G8 MATCHING-ADJUSTED INDIRECT COMPARISONS TO ASSESS COMPARATIVE EFFECTIVENESS: A SYSTEMATIC REVIEW OF APPLICATION IN SCIENTIFIC LITERATURE AND HEALTH TECHNOLOGY APPRAISALS
Thom H1, Jugl SM2, Nikoglou E3, Jawla S4, University of Bristol, Bristol, UK, 2Novartis Pharma AG, Basel, Switzerland, 3Product Lifecycle Services - NBS, Novartis Global Service Center Dublin, Dublin, Ireland, 4Novartis Healthcare Pvt. Ltd., Hyderabad, India

PRM160 G9 AN OUTCOMES REGRESSION APPROACH FOR INDIRECT COMPARISONS OF SURVIVAL OUTCOMES WHEN STANDARD NETWORK META-ANALYSIS IS NOT FEASIBLE
Jansen JP1, Jeffers A1, Chan K2, Incerti D1, 1Precision Health Economics, Oakland, CA, USA, 2Precision Health Economics, Vancouver, BC, Canada

PRM161 G10 OPTIMIZING SYSTEMATIC LITERATURE REVIEWS FOR THE CONDUCT OF NETWORK META-ANALYSES: SUGGESTIONS FOR GOOD PRACTICES
Pacou M1, Mesana L2, Belhadi D1, Gauthier A2, 1Amaris, Paris, France, 2Amaris, London, UK

RESEARCH ON METHODS - Study Design

PRM162 G11 MEANINGFUL MENTORSHIP ASSOCIATED WITH REWARDING SHORT-TERM RESEARCH: RESULTS FROM AN EVALUATION OF ISPOR STUDENT EXPERIENCES
Adamson BJ1, Lyons N2, Chou Y3, Gangan N4, Cannon-Dang E5, Chen C6, Law EH6, 1University of Washington, Seattle, WA, USA, 2Thomas Jefferson University, Philadelphia, PA, USA, 3University of North Carolina, Chapel Hill, NC, USA, 4Center for Pharmaceutical Marketing and Management, University of Mississippi, University, MS, USA, 5University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 6University of Illinois at Chicago, Chicago, IL, USA

PRM163 G12 QUALITY OF REPORTING IN SURGICAL RANDOMIZED CLINICAL TRIALS
Yu J1, Sun X2, Li Y1, Li X3, 1West China Hospital of Sichuan University, Chengdu, China, 2West China Hospital, Sichuan University, Chengdu, China, 3Chengdu Military General Hospital, Chengdu, China

PRM164 G13 A METHOD FOR IDENTIFYING PERIPHERAL INTRAVENOUS (PIV) CATHETER-RELATED COMPlications IN A U.S. HOSPITAL DISCHARGE DATABASE
Lim S1, Adams E2, Hyde R2, Danker III W2, Broder MS3, Chang E3, Reddy SR3, Tarbox M3, Bentley TG3, Ovington L2, 1Ethicon Inc, Somerville, NJ, USA, 2Ethicon, Inc., Somerville, NJ, USA, 3Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA

PRM165 G14 RELATIVE EFFICACY AND SAFETY OF LACOSAMIDE AS MONOTHERAPY FOR ADULTS WITH NEWLY DIAGNOSED FOcal SEIZURES: A NETWORK META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS
Kroep S1, Bouwmeester W1, Dimova S2, Zhang Y3, Borghs S2, Charokopou M3, 1Pharmerit BV, Rotterdam, The Netherlands, 2UCB Pharma, Brussels, Belgium, 3UCB Pharma, Raleigh, NC, USA

PRM166 G15 ASSESSING TRENDS OF DEVELOPING STUDENT INTERESTS WITHIN THE ISPOR STUDENT NETWORK, 2011 TO 2016
Gangan N1, Chou Y2, Adamson BJ3, Cannon-Dang E4, Chen C5, Law EH6, Lyons N4, 1Center for Pharmaceutical Marketing and Management, University of Mississippi, University, MS, USA, 2University of North Carolina, Chapel Hill, NC, USA, 3University of Washington, Seattle, WA, USA, 4Thomas Jefferson University, Philadelphia, PA, USA, 5University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 6University of Illinois at Chicago, Chicago, IL, USA

PRM167 G16 MEASURING THE VALIDITY AND RELIABILITY OF VALUE ASSESSMENT FRAMEWORKS FOR CANCER DRUGS: AN EVALUATION METHOD
Bentley TG1, Cohen JT2, Elkin EB3, Huynh J4, Mukherjea A5, Neville TH6, Mei MG7, Copher R8, Knoth RL9, Popescu I10, Lee J1, Zambrano JM1, Broder MS1,1Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 2Tufts Medical Center, Boston, MA, USA, 3Memorial Sloan-Kettering Cancer Center, New York, CA, USA, 4Hematology Oncology Medical Group of San Fernando Valley, Encino, CA, USA, 5California State University, East Bay, Hayward, CA, USA, 6David Geffen School of Medicine at UCLA, Department of Medicine, Los Angeles, CA, USA, 7City of Hope National Medical Center, Duarte, CA, USA, 8Eisai Inc., Woodcliff Lake, NJ, USA

PRM168 G17 RELEVANCE OF INDIRECT COMPARISON IN HAS ASSESSMENT
Hanna E1, Rémuzyat C2, Auquier P3, Jadot G4, Toumi M5, 1Aix-Marseille University, Marseille, France, 2Creativ-Ceutical, Paris, France, 3Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France, 4Lyon 1 University, Villeurbanne, France

PRM169 G18 PREFERRED INFORMATION SOURCES AND NEEDS OF CANCER PATIENTS ON DISEASE SYMPTOMS AND MANAGEMENT: A CROSS-SECTIONAL STUDY
Belachew SA, Mekuria Ab, Erku daA, University of Gondar, Gondar, Ethiopia

PRM170 G19 BARRIERS AND SOLUTIONS FOR REAL-WORLD CHART REVIEW EVIDENCE GENERATION
Stein D1, Ross L2,1Evidera, St-Laurent, QC, Canada, 2PPD, Waltham, MA, USA

PRM171 G20 IMPORTANCE OF CLINICAL OUTCOME ASSESSMENT (COA) DATA IN THE EVALUATION OF MEDICINES FOR THE TREATMENT OF RESTLESS LEGS SYNDROME (RLS): A REVIEW OF THE LABELS OF MEDICINES APPROVED BY THE FDA AND THE EMA
Perrier L1, Emery M1, Anfray C1, Acquado C2,1Mapi Research Trust, Lyon, France, 2Mapi, Lyon, France

PRM172 G21 SYSTEMATIC LITERATURE REVIEWS IN RARE DISEASES: CONSIDERATIONS, ISSUES AND RECOMMENDATIONS WHEN FACED WITH AN IMPERFECT EVIDENCE BASE
Gara A1, Mueller K1, Waser N1, Goring SM1, Thompson JC2,1ICON plc., Vancouver, BC, Canada, 2ICON plc., Abingdon, UK

PRM173 G22 METHODOLOGICAL CHALLENGES OF INDIRECT COMPARISONS IN HEMOPHILIA A
Booth J1, Lu M1, Lee H2, Valentino LA3,1Shire, Cambridge, MA, USA, 2Shire, Zurich, Switzerland, 3Shire, Chicago, IL, USA

PRM174 G23 MAKING THE MOST OF EXTERNAL COMPARATORS: A STUDY OF FRACTURE HEALING IN PATIENTS AT RISK OF NON-UNION
Mack C1, Pavesio A2, Kelly K2, Wester T2, Jones J2, Maislin G3, Irwin D4, Brinkley E1, Zura RD5,1QuintilesIMS, Durham, NC, USA, 2Bioventus LLC, Durham, NC, USA, 3Biomedical Statistical Consulting, Wynnewood, PA, USA, 4Truven Health Analytics, an IBM Company, Chapel Hill, NC, USA, 5Louisiana State University, New Orleans, LA, USA

PRM175 G24 IMPORTANCE OF CLINICAL OUTCOME ASSESSMENT (COA) DATA IN THE EVALUATION OF MEDICINES FOR THE TREATMENT OF ALZHEIMER’S DISEASE (AD): A REVIEW OF THE LABELS OF MEDICINES APPROVED BY THE FDA AND THE EMA
Perrier L1, Emery M1, Anfray C1, Acquado C2,1Mapi Research Trust, Lyon, France, 2Mapi, Lyon, France

PRM176 H1 CLINICAL MANAGEMENT AS A RESOURCE FOR COST STUDIES METHODOLOGY: AN EXAMPLE APPLIED TO NON-SMALL CELLS LUNG CANCER (NSCLC).
Paredes Fernandez D1, Lenz Alcayaga R2, Quirland-Lazo C1, Universidad de Chile, Santiago, Chile, 2Lenz Consultores, Santiago, Chile

RESEARCH ON METHODS - Conceptual Papers

PRM177 H2 COHORT ANALYSIS METHODS TO ESTIMATE THE BUDGET IMPACT OF ONCOLOGY TREATMENTS BY LINE OF THERAPY
O'Day K, Brown D, Xcenda, LLC, Palm Harbor, FL, USA

PRM178 H3 IMPROVING DISEASE MANAGEMENT THROUGH INSIGHTS GAINED FROM REAL-WORLD OBSERVATIONAL DATA
Mehta S1, Gani R2, Lang K3,1QuintilesIMS, Cambridge, MA, USA, 2QuintilesIMS, Berkshire, UK, 3QuintilesIMS, New York, NY, USA

PRM179 H4 HOW TO EVALUATE THE IMPACT OF A REAL-WORLD QUALITY IMPROVEMENT PROGRAM ON A MEANINGFUL HEALTH SYSTEM OUTCOME THAT HAS A POLICY IMPLICATION?
Rojanasarat S1, Carlson AM2,1University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence Consultants, LLC, Eden Prairie, MN, USA

PRM180 H5 THE USE OF QUALITATIVE (EXIT) INTERVIEWS IN CLINICAL TRIALS: VALUE, IMPLEMENTATION AND KEY CONSIDERATIONS
Gater A, Marshall C, Grant L, Wells J, Adelphi Values Ltd, Bollington, UK

**PRM181 H6**
DEFINING MULTI-AGENT CHEMOTHERAPY REGIMENS USING CLAIMS DATA ANALYSIS: IS THERE A ROLE FOR DATA VISUALIZATION?

Albarmawi H1, Onukwuha E1, Nagarajan M1, Gardner JF1, Yared JA2, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland, Greenebaum Cancer Center, Baltimore, MD, USA

**PRM182 H7**
MODELLING DISEASE PROGRESSION IN PATIENTS WITH GEOGRAPHIC ATROPHY

Tournier C1, Pope L1, Silverman D2, F.Hoffmann-La Roche AG, Basel, Switzerland, Roche Products Limited, Welwyn Garden City, UK

**PRM183 H8**
RWE DECODER: A DECISION MAKER’S FRAMEWORK FOR ASSESSING REAL WORLD EVIDENCE

Moloney RM1, Messner DA1, Stoto M2, Tunis S1, Center for Medical Technology Policy, Baltimore, MD, USA, 2Georgetown University, Washington, DC, USA

**PRM184 H9**
A WORKED EXAMPLE OF USING COMPUTER-ASSISTED QUALITATIVE DATA ANALYSIS SOFTWARE (CAQDAS) TO SUPPORT CONTENT VALIDITY IN PATIENT-CENTERED OUTCOMES RESEARCH

Marshall C, Grant L, Wells J, Williamson N, Gater A, Adelphi Values Ltd, Bollington, UK

**PRM185 H10**
A POTENTIAL SOLUTION MAKING EXPENSIVE TECHNOLOGIES AFFORDABLE UNDER BUDGET CONSTRAINTS IN UNIVERSAL HEALTH COVERAGE: CASE STUDY FOR JAPAN USING DIFFERENTIAL PRICING

Kamae I1, Sugimoto T2, Yamabe K3, 1The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan, 2The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan, Takeda Pharmaceutical Limited, Tokyo, Japan

**PRM186 H11**
EMBEDDING A VALUE FOCUS EARLY IN THE MEDICAL TECHNOLOGY INNOVATION PROCESS: INSIGHTS FROM 5 YEARS OF EXPERIENCE AT THE STANFORD BIODESIGN PROGRAM

Pietzsch JB, Yock CA, Peiffer V, Yock PG, Stanford University, Stanford, CA, USA

**PRM187 H12**
BEST PRACTICES FOR IMPROVED DESIGN AND EXECUTION OF “PIGGYBACK” HEALTH ECONOMIC STUDIES

Page MJ, Morris CA, Krahenbuhl J, Zhou R, Medpace, Cincinnati, OH, USA

**PRM188 H13**
USING REAL-WORLD DATA TO INFORM SMARTER CLINICAL TRIALS AND PROSPECTIVE OBSERVATIONAL STUDIES

Mehta S1, Mountford WK2, McDonald MR2, Stolper R1, Zakar J1, Lobeck F3, Christian JB3, Lang K2, 1QuintilesIMS, Cambridge, MA, USA, 2QuintilesIMS, New York, NY, USA, 3QuintilesIMS, Durham, NC, USA

**PRM190 H14**
ADDRESSING ECONOMIC EVALUATION NEEDS OF HOSPITAL DECISION-MAKERS IN THE UNITED STATES: A LITERATURE REVIEW AND RECOMMENDED FRAMEWORK FOR MEDICAL DEVICE BUDGET IMPACT MODELS

Delatore P1, Hollmann S2, Ferko N3, CR Bard Inc., Murray Hill, NJ, USA, Cornerstone Research Group Inc., Burlington, ON, Canada

**PRM191 H15**
AN APPROACH TO PHYSICIAN RECRUITMENT FOR EVIDENCE BASED STUDIES IN THE HOSPITAL SETTING

Glembot T1, Lessar S1, Ochoa Gautier JB2, 1Valley Health Metabolic & Bariatric Program, Winchester, VA, USA, 2Nestle Health Science, Florham Park, NJ, USA

**PRM193 H16**
NUANCES OF ASSESSING CLINICIAN AGREEMENT IN CLINICIAN REPORTED OUTCOMES (CLINROS)

Bender RH1, Lenderking WR2, Evidera, Bethesda, MD, USA, Evidera, Waltham, MA, USA

**PRM194 H17**
THE GET-REAL NAVIGATOR: SUPPORTING HTA AND PAYER EVALUATION OF NEW MEDICINES

Stegenga H1, Chambers MP2, Jonsson P3, Thwaites R4, Garner S1, 1National Institute for Health and Care Excellence, London, UK, 2MCHCE, London, UK, 3National Institute for Health and Care Excellence (NICE), Manchester, UK, 4Takeda, London, UK

**PRM195 H18**
ECONOMIC EVALUATIONS OF MEDICAL DEVICES - ISSUES AND CHALLENGES

Thokala P, ScHARR, The University of Sheffield, Sheffield, UK

---

**HEALTH CARE TREATMENT STUDIES**

**HEALTH SERVICES - Clinical Outcomes Studies**

**PHS1 H19**
CROSS-SECTIONAL ANALYSIS OF CYSTIC FIBROSIS RELATED DIABETES INPATIENT ADMISSIONS IN THE UNITED STATES

Ruban C1, Saunders W2, Marino J1, 1University of North Carolina Charlotte, Charlotte, NC, USA, 2UNC Charlotte College of Health and Human Services – Health Informatics, Charlotte, NC, USA
AN EXPLORATION OF DIABETES-RELATED HOSPITALIZATION DISCHARGE STATUS AND ITS ASSOCIATION WITH PERIPHERAL LOWER-EXTREMITY DISEASES
Zhao R1, Carlson AM2,1University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence Consultants, LLC, Eden Prairie, WA, USA

REAL-WORLD RATE OF DIAGNOSTIC REVISION AMONG PERIPHERAL T-CELL LYMPHOMA (PTCL) CASES
Jiao X1, Feliciano J2, Manley T2, Richhariya A2,1University of Southern California, Los Angeles, WA, USA, 2Seattle Genetics, Bothell, WA, USA

PATIENT CHARACTERISTICS AND HEALTH OUTCOMES IN CHILDREN DIAGNOSED WITH MARFAN SYNDROME IN THE UNITED STATES
Gordon BD1, Noone JM2, Zacherle E2, Whitmire SM3, Clark LA1, Howden R2, Blanchette CM2,1University of North Carolina at Charlotte, Charlotte, NC, USA, 2Precision Health Economics, Davidson, NC, USA, 3University of North Carolina; Precision Health Economics, Charlotte, NC, USA

THE USE OF E-HEALTH TO IMPROVE MEDICATION ADHERENCE AMONG PATIENTS WITH ASTHMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Jeminiwa RN1, Qian J2, Hansen RA1, Garza KB2, Fox BL1,1Harrison School of Pharmacy, Department of Health Outcomes Research and Policy, Auburn University, Auburn, AL, USA, 2Auburn University Harrison School of Pharmacy, Auburn, AL, USA

ESTIMATING THE EFFECT SIZE FOR CHANGES IN DEPRESSION AMONG COMMERCIALY-INSURED ADULTS USING THE MYSTRENGTH SELF-CARE PLATFORM
Schladweiler K, Rivera S, Hirsch A, myStrength, Inc, Denver, CO, USA

ACHIEVEMENT OF CLINICAL GOALS OF A CARDIOVASCULAR RISK MANAGEMENT PROGRAM FROM A COLOMBIAN POOR POPULATION. A CROSS-SECTIONAL STUDY.
Paz Wilches J1, Miranda Machado P2, Salcedo Mejia F2, De la Hoz Restrepo F3, Alvis Guzman N4,1Mutual Ser EPS, cartagena, Colombia, 2Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 3Mutual Ser EPS, Cartagena de Indias, Colombia, 4ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia

EFFECTIVENESS AND CLINICAL INERTIA IN ANTIDIABETIC THERAPY IN COLOMBIAN PATIENTS
Machado-Alba J1, Machado-Duque M2, Ramirez-Riveros C3,1Universidad Tecnológica de Pereira-Audifarma S.A., Pereira, Colombia, 2Universidad Tecnológica de Pereira, Pereira, Colombia, 3Hospital de Caldas, Pereira, Colombia

RISK OF THE FIRST MYOCARDIAL INFARCTION EVENT IN A CARDIOVASCULAR HEALTH PROMOTION PROGRAM OF A DEVELOPING COUNTRY “DE TODO CORAZON”. A COHORT STUDY.
Miranda Machado P1, Salcedo Mejia F1, Paz Wilches J2, De la Hoz Restrepo F3, Alvis Guzman N4,1Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 2Mutual Ser EPS, cartagena, Colombia, 3University Nacional de Colombia, Bogotá, D.C., Colombia, 4ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia

RISK OF THE FIRST STROKE EVENT IN A CARDIOVASCULAR HEALTH PROMOTION PROGRAM OF A DEVELOPING COUNTRY “DE TODO CORAZON”. A COHORT STUDY.
Alvis Guzman N1, Miranda Machado P2, Salcedo Mejia F2, Paz Wilches J3, De la Hoz Restrepo F4,1ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 2Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 3Mutual Ser EPS, cartagena, Colombia, 4Universidad Nacional de Colombia, Bogotá, D.C., Colombia

RISK OF THE FIRST CARDIOVASCULAR EVENT IN A CARDIOVASCULAR HEALTH PROMOTION PROGRAM OF A DEVELOPING COUNTRY “DE TODO CORAZON”. A COHORT STUDY.
De la Hoz Restrepo F1, Miranda Machado P2, Salcedo Mejia F2, Paz Wilches J3, Alvis Guzman N4,1Universidad Nacional de Colombia, Bogotá, D.C., Colombia, 2Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 3Mutual Ser EPS, cartagena, Colombia, 4ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia

RISK OF THE FIRST ACUTE HEART FAILURE EVENT IN A CARDIOVASCULAR HEALTH PROMOTION PROGRAM OF A DEVELOPING COUNTRY “DE TODO CORAZON”. A COHORT STUDY.
Miranda Machado P1, Salcedo Mejia F1, Paz Wilches J2, De la Hoz Restrepo F3, Alvis Guzman N4,1Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 2Mutual Ser EPS, cartagena, Colombia, 3Universidad Nacional de Colombia, Bogotá, D.C., Colombia, 4ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia
PHS13  
TRANSITION PROBABILITIES OF CHRONIC KIDNEY DISEASE IN A CARDIOVASCULAR RISK MANAGEMENT PROGRAM.

Alvis Guzman N1, Miranda Machado P2, Salcedo Mejia F3, Paz Wilches J3, De la Hoz Restrepo F4, Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 4Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 3Mutual Ser EPS, cartagena, Colombia, 4Universidad Nacional de Colombia, Bogotá, D.C., Colombia

PHS14  
INCREMENTAL HEALTHCARE EXPENDITURE OF ANXIETY DISORDERS AMONG US ADULTS WITH ARTHRITIS

Zhao X, Rai P, Ilobuchi C, Zhang Y, Tan X, West Virginia University, School of Pharmacy, Morgantown, WV, USA

PHS15  
EPIDEMIOLOGY OF POSTPARTUM DEPRESSION IN A MEDICAID POPULATION – A RETROSPECTIVE STUDY

Bonthapally V1, Breder MS2, Tieu RS3, Gannu L4, Meltzer-Brody S5, Chang E6, Sage Therapeutics, Inc., Cambridge, MA, USA, 2Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 3Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 4University of North Carolina, Chapel Hill, Chapel Hill, NC, USA

PHS16  
IMPACT OF TIME OF DIAGNOSIS ON PREVALENCE OF POSTPARTUM DEPRESSION IN WOMEN WITH COMMERCIAL AND MEDICAID HEALTH INSURANCE – A RETROSPECTIVE STUDY

Bonthapally V1, Breder MS2, Tieu RS3, Gannu L4, Meltzer-Brody S5, Chang E6, Sage Therapeutics, Inc., Cambridge, MA, USA, 2Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 3Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 4University of North Carolina, Chapel Hill, Chapel Hill, NC, USA

PHS17  
PREVALENCE AND HEALTHCARE UTILIZATION BURDEN ASSOCIATED WITH RHINOSINUSITIS IN A UNITED STATES COMMERCIALLY INSURED POPULATION

Khanna R1, Holy CE1, Romano A2,1Johnson & Johnson, New Brunswick, NJ, USA, 2Johnson & Johnson, Irvine, CA, USA

PHS18  
A REVIEW OF THE BURDEN OF HEPATITIS C VIRUS INFECTION IN KAZAKHSTAN

Almadiveya A, Ibrayev S, Turgambayeva A, Astana Medical University, Astana, Kazakhstan

PHS19  
BURDEN ATTRIBUTABLE TO CARDIOVASCULAR DISEASE AND CHRONIC KIDNEY DISEASE IN A COLOMBIAN POOR POPULATION

Miranda Machado P1, Salcedo Mejia F1, Paz Wilches J2, De la Hoz Restrepo F3, Alvis Guzman N4, Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 4Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 3Universidad Nacional de Colombia, Bogotá, D.C., Colombia, 4ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia

PHS20  
ESTIMATES OF POSTPARTUM DEPRESSION PREVALENCE IN A COMMERCIAL INSURED POPULATION – A RETROSPECTIVE ANALYSIS

Bonthapally V1, Breder MS2, Tieu RS3, Gannu L4, Meltzer-Brody S5, Chang E6, Sage Therapeutics, Inc., Cambridge, MA, USA, 2Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 3Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 4University of North Carolina, Chapel Hill, Chapel Hill, NC, USA

PHS21  
INCIDENCE OF CARDIOVASCULAR EVENTS IN A CARDIOVASCULAR HEALTH PROMOTION PROGRAM OF A DEVELOPING COUNTRY “DE TODO CORAZON”. A COHORT STUDY.

Alvis Guzman N1, Miranda Machado P2, Salcedo Mejia F3, Paz Wilches J3, De la Hoz Restrepo F4, Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 4Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 3Mutual Ser EPS, cartagena, Colombia, 4Universidad Nacional de Colombia, Bogotá, D.C., Colombia

PHS22  
ESTIMATED PREVALENCE OF POSTPARTUM DEPRESSION AMONG DELIVERIES BY WOMEN COVERED BY U.S. PRIVATE Payers

Carls GS1, Chawla A1, Epperson CN2, Chace M1, Bonthapally V3,3Analysis Group, Menlo Park, CA, USA, 2University of Pennsylvania, Philadelphia, PA, USA, 3Sage Therapeutics, Inc., Cambridge, MA, USA

PHS23  
PREVALENCE OF COMPLICATIONS IN PATIENTS WITH DIABETES MELLITUS IN COLOMBIA

Acuña L1, Bryón A2, Aschner P3, Chica LG4, Espin J3, Jaimes D3, Londoño D5, Lopez R2, Ruiz A3, Soler L7, Cuenta de Alto Costo, Bogotá, Colombia, 2HEORT, Bogota, Colombia, 3Pontificia Universidad Javeriana Medical School, Bogota, Colombia, 4Fundación Santa Fe de Bogotá, Bogota, Colombia, 5Andalusian School of Public Health, Granada, Spain, 6Fundacion Santa Fe de Bogotá, Bogota, Colombia, 7Risk Management Coordinator, Fondo Colombiano de Enfermedades de Alto Costo, Bogota, Colombia
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHS24</td>
<td>Determination of Chronic Venous Disease Prevalence Among at-risk Individual Employing Clinical Validated Scoring Patient-centered Outcomes</td>
<td>Yoma T1, Udombhornprabha A2, Netwila A2, Klongpiyapong P2, 1Eastern Asia University School of Pharmacy &amp; Vribhavadi General Hospital, Pathumthani, Thailand, 2Eastern Asia University School of Pharmacy, Pathumthani, Thailand</td>
</tr>
<tr>
<td>PHS25</td>
<td>Hospital Volume and 30-Day Readmission Rates Among Patients with Pneumonia</td>
<td>Carlson KB1, Dabbous F2, Kabir C1, Nitti K1, Blair C1, Summerfelt T1, Advocate Health Care, Oak Lawn, IL, USA, 2Russell Institute for Research &amp; Innovation, Park Ridge, IL, USA</td>
</tr>
<tr>
<td>PHS26</td>
<td>Dyslipidemia in the &quot;De Todo Corazon&quot; Program. A Cross-Sectional Study.</td>
<td>Paz Wilches J1, Miranda Machado P1, Salcedo Mejia F2, De la Hoz Restrepo F3, Alví Guzman N4, 1Mutual Ser EPS, Cartagena, Colombia, 2Alzak Foundation. Universidad de Cartagena, Cartagena de Indias, Colombia, 3University Nacional de Colombia, Bogotá, D.C., Colombia, 4ALZAK Foundation. Universidad de Cartagena, Cartagena de Indias, Colombia</td>
</tr>
<tr>
<td>PHS27</td>
<td>Assessment of Cardiovascular Risk in the &quot;De Todo Corazon&quot; Program in a Colombian Poor Population. A Cross-Sectional Study.</td>
<td>Miranda Machado P1, Salcedo Mejia F1, Paz Wilches J2, De la Hoz Restrepo F1, Alví Guzman N4, 1University of Cartagena, Alzak Foundation, Cartagena de Indias, Colombia, 2Mutual Ser EPS, cartagena, colombia, 3University Nacional de Colombia, Bogotá, D.C., Colombia, 4ALZAK Foundation. Universidad de Cartagena, Cartagena de Indias, Colombia</td>
</tr>
<tr>
<td>PHS28</td>
<td>The Impact of Pharmacist Based Diabetes Treatment on the Odds of HbA1C Reduction Among Medicaid Patients</td>
<td>Simmons D1, McCarthy C2, Bateman MT3, McGuigan KA3, Wagner ML2, 1Rutgers University, Piscataway, NJ, USA, 2Rutgers, The State University of NJ, Piscataway, NJ, USA, 3Teva Pharmaceutical Industries Ltd., Frazer, PA, USA</td>
</tr>
<tr>
<td>PHS29</td>
<td>Assessment of Cardiovascular Diseases Risk in Patients with Type 2 Diabetes Mellitus</td>
<td>Jose C1, Indegen private limited, Bangalore, India</td>
</tr>
<tr>
<td>PHS30</td>
<td>Metabolic Profiles in Spousal Alzheimer Caregivers with Poor Subjective Sleep Quality</td>
<td>Yeung P1, Jen R2, Vaida F3, Mausbach B3, 1University of California San Diego, La Jolla, CA, USA, 2University of British Columbia, Vancouver, BC, Canada, 3University of California San Diego, San Diego, CA, USA</td>
</tr>
</tbody>
</table>

**HEALTH SERVICES - Cost Studies**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHS33</td>
<td>A National Budget Impact Analysis of a Specialised Surveillance Program for Individuals at Very High Risk of Melanoma in Australia</td>
<td>Watts CG, The University of Sydney, Camperdown, Australia</td>
</tr>
<tr>
<td>PHS34</td>
<td>Migraine in Obese Adults and Its Impact on Health Care Expenses</td>
<td>Wu J1, Davis-ajami ML2, Lu K3, 1Presbyterian College, Clinton, SC, USA, 2Virginia Commonwealth University, Richmond, VA, USA, 3University of South Carolina, Columbia, SC, USA</td>
</tr>
<tr>
<td>PHS35</td>
<td>State Medicaid Cost Savings from the New York University Caregiver Intervention for Families Coping with Dementia</td>
<td>Long KH1, Moriarty JP2, Farseth PH3, Mittelman MS4, Foldes SS5, 1K.Long Consulting, LLC, St. Paul, MN, USA, 2Mayo Clinic Rochester, Rochester, MN, USA, 3Minnesota Department of Human Services, St. Paul, MN, USA, 4New York University School of Medicine, New York, NY, USA, 5Foldes Consulting LLC, Saint Louis Park, MN, USA</td>
</tr>
<tr>
<td>PHS36</td>
<td>Estimating the Incremental Effect of Diabetes Complications to Diabetes-related Hospitalization Cost</td>
<td>Zhao R1, Carlson AM2, 1University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence Consultants, LLC, Eden Prairie, MN, USA</td>
</tr>
<tr>
<td>PHS37</td>
<td>Economic Impact of Routine Opt-Out Antenatal HIV Screening: A Systematic Review™</td>
<td>Ibekwe E, 1Ibekwe E, Prof Francis Fatoye F, Haigh C, Manchester Metropolitan University, Manchester, UK</td>
</tr>
</tbody>
</table>
**PHS38 J6** ASSOCIATION OF COMORBID DEPRESSION WITH HEALTH CARE EXPENDITURES IN ADULTS WITH RHEUMATOID ARTHRITIS

Khairnar R, University of Maryland, Baltimore, MD, USA

**PHS39 J7** HEALTHCARE RESOURCE UTILIZATION AND COSTS OF CARE FOR MESOTHELIOMA MEDICARE BENEFICIARIES

Fryzek J, Rutterbusch J, Garabrant D, Dalvi T, Beebe-Dimmer J, Sidransky E, Gathiersburg, MD, USA, 2Karmanos Cancer Institute, Detroit, MI, USA, 3AstraZeneca, 4Karmanos Cancer Institute, Detroit, MI, USA

**PHS40 J8** COMPARISON OF HOSPITAL COSTS VS OUTPATIENT OF APPLICATION OF INTRAVENOUS INJECTABLE THERAPY IN THE TREATMENT OF PERIPHERAL OCCLUSIVE ARTERIAL DISEASE IN COLOMBIA

Tamayo C, Upegui A, Robles A, Puentes SY, Universidad Nacional, Bogota, Colombia, 2Universidad Externado, Bogota, Colombia, 3ECCI, Bogota, Colombia

**PHS41 J9** ENROLLMENT PATTERNS FOR HOSPICE AND COST OF END-OF-LIFE CARE AMONG ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A SEER-MEDICARE ANALYSIS

Kumar AJ, Winn A, Shah GL, Lin P, Parsons SK, Tufts Medical Center, Boston, MA, USA, 2The University of North Carolina at Chapel Hill, Chapel Hill, MA, USA, 3Memorial Sloan Kettering Cancer Center, New York, NY, USA

**PHS42 J10** BURDEN OF ILLNESS IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMORS

Burton T, Ye X, Parker E, Bancroft T, Healey JH, Optum, Boston, MA, USA, 2Daichi Sankyo Pharma Development, Edison, NJ, USA, 3Optum, Eden Prairie, MN, USA, 4Memorial Sloan Kettering Cancer Center, New York, NY, USA

**PHS43 J11** A 10-YEAR REVIEW OF ACUTE MYOCARDIAL INFARCTION HEALTH CARE COSTS IN ALBERTA, CANADA

Tran DT, Welsh R, Ohinnma A, Nguyen T, Kaul P, University of Alberta, Edmonton, AB, Canada, 2Institute of Health Economics, Edmonton, AB, Canada

**PHS44 J12** COST OF CONGESTIVE HEART FAILURE: THE CASE OF AN INSURED COLOMBIAN POPULATION

Carrasquilla Sotomayor M, Alvis-Zakzuk N, Moreno Ruiz D, Alvis-Guzman N, Alzak Foundation, Universidad de Cartagena, Cartagena de Indias, Colombia, 2ALZAK Foundation, Cartagena, Colombia, 3Alzak foundation, Cartagena, Colombia, 4Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, 5ALZAK Foundation. Universidad de Cartagena, Cartagena de Indias, Colombia

**PHS45 J13** HEALTH CARE COSTS OF STROKE IN CARDIOVASCULAR RISK PATIENTS IN INSURED COLOMBIAN POOR POPULATION

Carrasquilla Sotomayor M, Moreno Ruiz D, Martinez-Zarzuk J, Paz Wilches J, Alvis-Guzman N, Alzak Foundation. Universidad de Cartagena, Cartagena de Indias, Colombia, 2ALZAK Foundation, Cartagena, Colombia, 3Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, 4Alzak foundation, Cartagena, Colombia, 5Mutual Ser EPS, cartagena, Colombia, 6ALZAK Foundation. Universidad de Cartagena, Cartagena de Indias, Colombia

**PHS46 J14** INCREMENTAL HEALTHCARE COSTS AND PRODUCTIVITY COSTS ASSOCIATED WITH DEPRESSION AMONG WORKING AGE (18 TO 64 YEARS) ADULTS WITH RHEUMATOID ARTHRITIS

Deb A, Meraya AM, Sambamoorthi U, West Virginia University, School of Pharmacy, Morgantown, WV, USA

**PHS47 J15** DIRECT MEDICAL COSTS DUE TO HYPERTENSION IN A COLOMBIAN POOR POPULATION, A TOP-DOWN MACRO COSTING ANALYSIS

Alvis Zakzuk J, Carrasquilla-Sotomayor M, Moreno Ruiz D, Paz Wilches J, Martinez-Zarzuk J, Alvis-Zakzuk NR, Alvis-Guzman N, Alzak foundation, Cartagena, Colombia, 2ALZAK Foundation, Cartagena, Colombia, 3Universidad de Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, 4Mutual Ser EPS, cartagena, Colombia, 5ALZAK Foundation. Universidad de Cartagena, Cartagena de Indias, Colombia

**PHS48 J16** EVALUATING THE ECONOMIC BURDEN AND HEALTH CARE UTILIZATION DUE TO DEPRESSION COMORBIDITY IN DEMENTIA

Desai R, Nayak R, St. John's University, Jamaica, NY, USA
PHS49 J17 ASTHMA-RELATED DIRECT COSTS AND HEALTH CARE UTILIZATION BY SEVERITY IN COLOMBIA
Florez Tanus A1, Parra DM2, Zakzuk J3, Alvis Guzman N4, Caraballo L5, Marrugo Arnedo C6, Gomez de la Rosa F7,8Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoleón Franco Pareja. Centro de Investigación e Innovación en salud, Cartagena de Indias, Colombia, 2University of Cartagena. Health Economics Research Group., Cartagena de Indias. Bolivar, Colombia, 3University of Cartagena.Institute for Immunological Research., Cartagena, Colombia, 4ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 5University of Cartagena.Institute for Immunological Research. Fundemeb., Cartagena, Colombia, 6Universidad de Cartagena. Centro de investigación e innovación en salud-CIISA, Cartagena de Indias, Colombia, 7ALZAK Foundation, Cartagena, Colombia

PHS50 J18 HEALTH CARE COSTS OF ACUTE MYOCARDIAL INFARCTION IN A COLOMBIAN POPULATION AFFILIATED TO A CARDIOVASCULAR RISK-MANAGEMENT PROGRAM: A MACRO COSTING ANALYSIS
Alvis Zakzuk J1, Carrasquilla-Sotomayor M2, Moreno Ruiz DV3, Martinez-Zarzuk J4, Alvis-Zakzuk NR5, Gomez de la Rosa F6, Alvis Guzman N7,1Alzak foundation, Cartagena, Colombia, 2ALZAK Foundation, Cartagena, Colombia, 3University of Cartagena, Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, 4ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia

PHS51 J19 PRIMARY OPEN ANGLE GLAUCOMA: A REAL WORLD EVIDENCE ANALYSIS OF ASSOCIATED PREVALENT AND INCIDENT COSTS AND HEALTHCARE RESOURCE UTILIZATION
Arnold RJ1, Layton AJ2, Francis BA3, Quorum Consulting, Inc, San Francisco, CA, USA, 2UCLA, Los Angeles, CA, USA

PHS52 J20 IMPACT OF DISEASE SEVERITY AND COMORBIDITY ON INFORMAL COSTS IN DEMENTIA: A SYSTEMATIC REVIEW OF AVAILABLE EVIDENCE
Shrikhande M1, Desai R2, Castro TD3, Ohanian S1, Nayar R2, St.John's University, Jamaica, NY, USA, 2St. John's University, Jamaica, NY, USA

PHS53 J21 HEALTHCARE BURDEN AMONG PATIENTS NEWLY DIAGNOSED WITH MULTIPLY MYELOMA WITH COMMERCIAL AND MEDICARE INSURANCE COVERAGE IN THE US

PHS54 J22 DIRECT COSTS FOR PATIENTS WITH CHRONIC KIDNEY DISEASE FROM A CARDIOVASCULAR RISK MANAGEMENT PROGRAM IN A COLOMBIAN POOR POPULATION
Moreno Ruiz DV1, Alvis Zakzuk J2, Martinez Zakzuk J3, Carrasquilla Sotomayor M4, Alvis Zakzuk R5, Paz Wilches JJ6, Alvis Guzman N7,1Alzak foundation, Cartagena, Colombia, 2Alzak foundation, Cartagena, Colombia, 3Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 4Mutual ser, Cartagena-Bol, Colombia, 5ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia

PHS55 J23 HEPATITIS C COST STUDY C, BRAZIL, 2014
Itria A, Mendes GB,GOIAS UNIVERSITY, goiânia, Brazil

PHS56 J24 HEALTH CARE COSTS DUE TO DIABETES MELLITUS 2 IN A COLOMBIAN POOR POPULATION AFFILIATED TO A CARDIOVASCULAR RISK MANAGEMENT PROGRAM
Martinez-Zarzuk J1, Moreno Ruiz DV2, Alvis Zakzuk J3, Paz Wilches J4, Carrasquilla-Sotomayor M5, Alvis-Zakzuk NR6, Alvis Guzman N7,1ALZAK Foundation, Cartagena, Colombia, 2University of Cartagena. Centro de Investigación y Docencia, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias, Colombia, 3Mutual Ser EPS, cartagena, Colombia, 4ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia

PHS57 J25 EVALUATION OF MEDICAL RESOURCE USE AND COSTS AMONG PATIENTS WITH NON-CARDIOEMBOLIC ISCHEMIC STROKE IN BEIJING
Wei C1, Fan D2, WANG Y2, PAN Y3, HAN Q4, HU Y1,1Peking University Health Science Center, Beijing, China, 2Peking University Third Hospital, Beijing, China, 3Capital Medical University, Beijing Tiantan Hospital, Beijing, China, 4Hospital Health Insurance Management Committee of Chinese Hospital Association, Beijing, China

PHS58 J26 MEDICAL COSTS ASSOCIATED WITH 30-DAY READMISSIONS AMONG PATIENTS WITH HEART FAILURE AND PERSISTENT HYponATREMIA
Amin A1, Sundar S2, Chase S2, Harmon AL3, Kamat SA4, Ortendahl JD5,1University of California, Irvine, CA, USA, 2Otsuka Pharmaceutical Development & Commercialization, Princeton, NJ, USA, 3Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA

PHS59 K1 ECONOMIC BURDEN OF VERY PRETERM BIRTH: A SYSTEMATIC LITERATURE REVIEW
ECONOMIC IMPACT OF UNINTENTIONAL CARBON MONOXIDE POISONING IN THE UNITED STATES

Ran T, Nurmagambetov T, Sircar K, Centers for Disease Control and Prevention, Atlanta, GA, USA.

COSTS OF THE ACUTE OTITIS MEDIA IN PEDIATRICS, IN A CITY OF THE COLOMBIAN CARIBBEAN COAST


ASSOCIATION BETWEEN ASTHMA MEDICATION USE AND TOTAL HEALTHCARE COSTS AMONG PATIENTS WITH ASTHMA

Dave I, Nagar SP, Arif AA, Laditka SB, Huber LR, University of North Carolina Charlotte, Charlotte, NC, USA.

BURDEN OF ILLNESS IN CYSTIC FIBROSIS: A RETROSPECTIVE ANALYSIS OF MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA

Vadagam P, Kamal KM, Mukherjee K, Covvey JR, Giannetti V, Duquesne University Mylan School of Pharmacy, Pittsburgh, PA, USA.

HEALTHCARE RESOURCE UTILIZATION AND COSTS OF RENAL IMPAIRMENT IN PATIENTS WITH MULTIPLE MYELOMA

Bhowmik D, Song X, Intorcia M, Bristol-Myers Squibb, Plainsboro, NJ, USA.

TOTAL COST OF CARE AMONG PATIENTS WITH EXTENSIVE DISEASE SMALL CELL LUNG CANCER (ED-SCLC)

Danese M, Gleseson M, Lubeck D, Bobiak S, Outcomes Insights, Inc., Westlake Village, CA, USA.

COST-EFFECTIVENESS ANALYSIS OF A KIDNEY TRANSPLANT PROGRAM IN A PRIVATE, PHILANTHROPIC AND TERTIARY HOSPITAL IN BRAZIL

Malheiro DT, Matos AC, Pacheco-Silva A, Neto MC, Hospital Israelita Albert Einstein, São Paulo, Brazil.

COST EFFECTIVENESS OF STROKE UNIT EQUIVALENT CARE FOLLOWED BY EARLY SUPPORTED DISCHARGE IN RURAL AREA


TO EVALUATE THE COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA WHO HAVE RECEIVED CHEMOTHERAPY/ CHEMOTHERAPY WITH STEM CELL TRANSPLANTATION AS FIRST LINE THERAPY FROM A US HEALTHCARE PERSPECTIVE.

Patidar M, Campbell JD, University of Colorado Denver, Aurora, CO, USA.

COST EFFECTIVENESS OF A HOME VISITATION PROGRAM FOR MOTHERS WITH POSTPARTUM DEPRESSIVE SYMPTOMS


MINIMUM COST-ANALYSIS OF METASTATIC MELANOMA TREATMENT BASED ON PATIENT’S WEIGHT


LONGTERM CLINICAL AND ECONOMIC OUTCOMES OF INTENSIVE VS STANDARD BLOOD PRESSURE REDUCTION IN NON-DIABETICS AT HIGH CARDIOVASCULAR RISK - EXTRAPOLATIONS FROM THE SPRINT TRIAL

Geisler B, Acharya B, Shrestha A, Pietzsch JB, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
PHS72  K14  COST UTILITY ANALYSIS OF A HEART FAILURE CLINIC PROGRAM IN A SPECIALIZED CLINIC IN COLOMBIA
Saldarriaga C1, Gonzalez N2, Orozco JP1, Universidad de Antioquia, Medellin, Colombia, 1Clinica CardioVID, Medellin, Colombia, 2Medtronic PLC, Medellin, Colombia

PHS73  K15  ESTIMATING HEALTH BENEFITS AND COST-SAVINGS FOR REDUCING THE INCIDENCE OF INVASIVE COLORECTAL CANCER IN THE UNITED STATES
Hung M1, Ekwueme D1, King JB1, Chang S2, US CDC, Atlanta, GA, USA, 2School of Medicine, Washington University, St. Louis, MO, USA

PHS74  K16  HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH MANAGING DISEASE- AND TREATMENT-RELATED HEALTH EVENTS IN US MULTIPLE MYELOMA (MM) PATIENTS: REAL-WORLD ADMINISTRATIVE CLAIMS BASED ANALYSIS
Maiese EM1, Kish J2, Raje N3, Mujumdar U2, Laney J2, Nero D2, Mehta S2, Feinberg B2,1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2Cardinal Health Solutions, Dallas, TX, USA, 3Massachusetts General Hospital Cancer Center, Boston, MA, USA

PHS75  K17  A REAL-WORLD CLAIMS ANALYSIS OF GliOBLASTOMA COST OF CARE IN THE UNITED STATES
Norden A1, You M2, Dastani H3, Bobiak S3, Korytowsky B3, Singh P3,1Dana-Farber/Brigham and Women's Cancer Institute, Boston, MA, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Bristol-Myers Squibb, Princeton, NJ, USA

PHS76  K18  HEALTHCARE UTILIZATION AND COSTS IN LUNG CANCER PATIENTS WITH PRE-EXISTING COPD AMONG SEER-MEDICARE BENEFICIARIES
Shah S1, Blanchette CM2, Arthur S1, Coyle JP1, Kowalkowski M3, Howden R1,1University of North Carolina at Charlotte, Charlotte, NC, USA, 2Precision Health Economics, Davidson, NC, USA, 3Levine Cancer Institute, Charlotte, NC, USA

PHS77  K19  THE IMPACT OF COMORBID CONDITIONS ON HOSPITAL RESOURCE UTILIZATION AMONG PATIENTS WITH CYSTIC FIBROSIS
Craver C, Belk K, Vizient Inc., Mooresville, NC, USA

PHS78  K20  HEALTHCARE RESOURCE UTILIZATION AND COSTS-associated WITH COMORBIDITIES AMONG HIV-POSITIVE PATIENTS
Lachaine J1, Baribeau V2, Lorgeoux R3, Tossonian H1, Université de Montréal, Montreal, QC, Canada, 2PeriPharm Inc., Montreal, QC, Canada, 3Gilead Sciences Canada, Mississauga, ON, Canada

PHS79  K21  UTILIZATION AND COST OF HEALTHCARE SERVICES DURING EPISODES OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) INVOLVING ADMISSION TO UNITED STATES (US) HOSPITALS: A RETROSPECTIVE OBSERVATIONAL ANALYSIS USING A LARGE HEALTHCARE CLAIMS DATABASE
Keyloun K1, Murphy B2, Gillard P1, Berger A2,1Allergan plc, Irvine, CA, USA, 2Evidera, Lexington, MA, USA

PHS80  K22  HEALTHCARE RESOURCE UTILIZATION AND COSTS IN HIV-POSITIVE VERSUS HIV-NEGATIVE PATIENTS
Lachaine J1, Baribeau V2, Lorgeoux R3, Tossonian H1, Université de Montréal, Montreal, QC, Canada, 2PeriPharm Inc., Montreal, QC, Canada, 3Gilead Sciences Canada, Mississauga, ON, Canada

PHS81  K23  HEALTHCARE UTILIZATION AND SURVIVAL ASSOCIATED WITH CLINICAL CARE PATHWAY FOR RECTAL CANCER TREATMENT
Campolina AG1, Kobayashi ST2, Soarez PC3, Diz MD4,1Cancer Institute of the State of Sao Paulo, Sao Paulo, Brazil, 2Instituto do Cancer do Estado de Sao Paulo - Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, 3Sao Paulo University, Sao Paulo, Brazil, 4Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, Brazil

PHS82  K24  HEALTHCARE RESOURCE UTILIZATION AND COSTS OF METASTATIC NON-SMALL CELL LUNG CANCER IN SELECT EUROPEAN COUNTRIES
Kurosky S1, Lorenzo M2, Cygun Carter G3, Parikh RC1, Winfree K3, Kaye JA4,1RTI Health Solutions, Research Triangle Park, NC, USA, 2Eli Lilly and Company Limited, Windlesham, UK, 3Eli Lilly and Company, Indianapolis, IN, USA, 4RTI Health Solutions, Waltham, MA, USA

PHS83  L1  SICKLE CELL DISEASE INPATIENT DATA ANALYSIS OF MEDICARE PATIENTS
Saunders W1, Ruban C2,1UNC Charlotte College of Health and Human Services – Health Informatics, Charlotte, NC, USA, 2University of North Carolina Charlotte, Charlotte, NC, USA

PHS84  L2  THE LONG-TERM IMPACT OF PULMONARY EXACERBATIONS AMONG PATIENTS WITH CYSTIC FIBROSIS (CF) IN COMMERCIAL MANAGED CARE PLANS
Hassan M1, Bonafede MM2, Limone B2, Stenson K1,1Vertex Pharmaceuticals Incorporated, Boston, MA, USA, 2Truven Health Analytics, Cambridge, MA, USA
### HEALTH SERVICES - Patient-Reported Outcomes & Patient Preference Studies

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHS87 L5</td>
<td>COST OF VISITS ASSOCIATED WITH MANAGEMENT OF INTERNATIONAL NORMALIZED RATIO (INR) RESULTS IN ATRIAL FIBRILLATION (AF) PATIENTS TREATED WITH VITAMIN K ANTAGONIST (VKA)</td>
<td>Ansolabehere X1, Augier G2, QuintilesIMS, Paris La Défense, France, Axess Research, Limonest, France</td>
</tr>
<tr>
<td>PHS86 L4</td>
<td>DRIVERS OF HOSPITAL UTILIZATION AMONG PATIENTS WITH SPINAL MUSCULAR ATROPHY</td>
<td>Craver C, Belk K, Vizient Inc., Mooresville, NC, USA</td>
</tr>
</tbody>
</table>

**PHS85 L3**  
**PHS88 L6**  
**PHS89 L7**  
**PHS90 L8**  
**PHS91 L9**  
**PHS92 L10**  
**PHS93 L11**  
**PHS94 L12**  
**PHS95 L13**  
**PHS96 L14**  
**PHS97 L15**  
**PHS98 L16**
**QUALITATIVE STUDY IN GONDAR TOWN, ETHIOPIA**

**MANAGEMENT OF MINOR AILMENTS IN A COMMUNITY PHARMACY SETTING: FINDINGS FROM A PHARMACY IN GONDAR TOWN, ETHIOPIA**

**ONLINE MANAGEMENT OF MAJOR AILMENTS AMONG ETHIOPIAN ELDERLY IN COMMUNITY PHARMACIES**

**CORRELATES OF GOOD DIABETES MANAGEMENT AMONG AMERICANS WITH TYPE 2 DIABETES**

**DETERMINANTS OF GOOD DIABETES MANAGEMENT AMONG AMERICANS WITH TYPE 2 DIABETES**

**AMONG MARRIED WOMEN ATTENDING TERTIARY CARE HOSPITAL QUETTA, PAKISTAN**

**ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE AMONG PATIENTS WITH TUBERCULOSIS IN GOVERNMENT INFECTIOUS DISEASE HOSPITAL, GUNTUR, INDIA**

**ANALYSIS OF FORMULARY COVERAGE AND COST OF HUMAN IMMUNODEFICIENCY VIRUS ANTIRETROVIRAL DRUGS IN MEDICARE PART D (2006-2015)**

**FINANCIAL INFLUENCE OF CURRENT AND ALTERNATIVE PRICING BENCHMARKS FOR PHARMACY DISPENSED MEDICATIONS IN CALIFORNIA WORKERS’ COMPENSATION SYSTEM**

**INVESTIGATION OF RELATIONSHIP BETWEEN DEMOGRAPHICS AND TYPE 2 DIABETES MORTALITY IN TWO TERTIARY HOSPITALS IN SOUTHEAST NIGERIA:**

**HOSPITAL REIMBURSEMENT UNDER THE MEDICARE PPS: WHAT IS THE RELATIONSHIP BETWEEN COST AND QUALITY?**

**METABOLIC CONTROL IN PATIENTS WITH DIABETES MELLITUS TYPE 2 IN A DISEASE MANAGEMENT PROGRAM FROM PRIVATE HEALTH INSURER IN COLOMBIA**

**DETERMINANTS OF PATIENT-CENTRED CARE FROM THE PUBLIC AND PROFESSIONALS’ PERSPECTIVES**

**CORRELATES OF GOOD DIABETES MANAGEMENT AMONG AMERICANS WITH TYPE 2 DIABETES**

**MANAGEMENT OF MINOR AILMENTS IN A COMMUNITY PHARMACY SETTING: FINDINGS FROM A QUALITATIVE STUDY IN GONDAR TOWN, ETHIOPIA**

---

**HEALTH SERVICES - Health Care Use & Policy Studies**

**ONE-YEAR PREVALENCE AND HEALTH CARE UTILIZATION OF DIABETES IN LUNG CANCER-RELATED INPATIENT ADMISSIONS IN THE UNITED STATES**

**DEVELOPMENT OF AN EYE DROP COMFORT MEASURE FOR TOPICAL OCULAR DROP APPLICATION**

**ASSESSMENT OF KNOWLEDGE ATTITUDE AND PRACTICE OF FAMILY PLANNING AMONG MARRIED WOMEN ATTENDING TERTIARY CARE HOSPITAL QUETTA, PAKISTAN**

**ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE AMONG PATIENTS WITH TUBERCULOSIS IN GOVERNMENT INFECTIOUS DISEASE HOSPITAL, GUNTUR, INDIA**

---

**EXPLORING CONSUMERS’ DECISION MAKING FOR USING COMPREHENSIVE MEDICATION REVIEW (CMR) SERVICE**

**HOW COMMON ARE DIGITAL WRAP-AROUND PRODUCT TIE-INS WITH FDA-APPROVED NEW MARKET ENTRANTS?**

**ANALYSIS OF FORMULARY COVERAGE AND COST OF HUMAN IMMUNODEFICIENCY VIRUS ANTIRETROVIRAL DRUGS IN MEDICARE PART D (2006-2015)**

**FINANCIAL INFLUENCE OF CURRENT AND ALTERNATIVE PRICING BENCHMARKS FOR PHARMACY DISPENSED MEDICATIONS IN CALIFORNIA WORKERS’ COMPENSATION SYSTEM**

**INVESTIGATION OF RELATIONSHIP BETWEEN DEMOGRAPHICS AND TYPE 2 DIABETES MORTALITY IN TWO TERTIARY HOSPITALS IN SOUTHEAST NIGERIA:**

---

**HOSPITAL REIMBURSEMENT UNDER THE MEDICARE PPS: WHAT IS THE RELATIONSHIP BETWEEN COST AND QUALITY?**

**METABOLIC CONTROL IN PATIENTS WITH DIABETES MELLITUS TYPE 2 IN A DISEASE MANAGEMENT PROGRAM FROM PRIVATE HEALTH INSURER IN COLOMBIA**

**DETERMINANTS OF PATIENT-CENTRED CARE FROM THE PUBLIC AND PROFESSIONALS’ PERSPECTIVES**

**CORRELATES OF GOOD DIABETES MANAGEMENT AMONG AMERICANS WITH TYPE 2 DIABETES**

**MANAGEMENT OF MINOR AILMENTS IN A COMMUNITY PHARMACY SETTING: FINDINGS FROM A QUALITATIVE STUDY IN GONDAR TOWN, ETHIOPIA**
PHS114 M8 GENDER DIFFERENCES IN HEART FAILURE IN A REAL WORLD CONTEST: IMPACT ON DRUG UTILIZATION AND COSTS FOR THE MANAGEMENT OF THIS CLINICAL CONDITION.

Ayele AA, university of Gondar, gondar, Ethiopia

PHS115 M9 MEDICINES SEEKING AND TAKING BEHAVIOUR AMONG GENERAL PUBLIC IN THE STATE OF PENANG, MALAYSIA

Dawood OT, Hassali MA, Saleem F, Universiti Sains Malaysia, Penang, Malaysia, University of Baluchistan, Quetta, Pakistan

PHS116 M10 TRENDS IN 30-DAY READMISSION RATES AMONG PATIENTS WITH CONGESTIVE HEART FAILURE: RESULTS FROM A LARGE, SINGLE HEALTHCARE ORGANIZATION

Dabbous E, Kozmic S, Zamfirova I, Carlson KB, Summerfelt WT, Chaptini N, Russell Institute for Research & Innovation, Park Ridge, IL, USA, Advocate Health Care, Oak Lawn, IL, USA, Advocate Health Care, Downers Grove, IL, USA, Advocate Lutheran General Hospital, Park ridge, IL, USA


Navaratnam P, Friedman H, Navaratnam A, DataMed Solutions LLC., New York, NY, USA, Sygeny Ltd, Helsinki, Finland

PHS119 M12 KNOWLEDGE AND PRACTICE OF NURSES TOWARDS PREVENTION OF PRESSURE ULCER AND ASSOCIATED FACTORS IN GONDAR UNIVERSITY HOSPITAL, NORTHWEST ETHIOPIA

Amidie FZ, Nuru N, University of Gondar, Gondar, Ethiopia

PHS120 M13 A COMPREHENSIVE REVIEW OF ORPHAN DRUGS POLICIES, PROCEDURE, LEGISLATION, REGULATION, ESTABLISHED IN THE UNITED STATES AND AUSTRALIA

Hussain S, MCPHS University, Allston, MA, USA

PHS121 M14 USE OF ORAL CHEMOTHERAPY DRUGS AND FALLING INTO THE COVERAGE GAP IN MEDICARE CANCER SURVIVORS

Yuan J, Lu KZ, Wu J, University of South Carolina, Columbia, SC, USA, Presbyterian College, Clinton, SC, USA

PHS122 M15 NATIONAL DISEASE AND ECONOMIC BURDEN OF MULTIPLE SCLEROSIS IN TAIWAN

Hsu JC, Chou C, National Cheng Kung University, Tainan, Taiwan

PHS123 M16 GEOGRAPHICAL DIFFERENCE IN PROCESSES OF CARE IN CHRONIC KIDNEY DISEASE AMONG MEDICARE PART D ENROLLEES

Han Y, Balkrishnan R, University of Michigan, Ann Arbor, WV, USA, University of Virginia School of Medicine, Charlottesville, VA, USA

PHS124 M17 STATIN UTILIZATION AMONG PATIENTS WITH DIABETES IN AN EMPLOYER-SPONSORED PHARMACIST PROGRAM

Calabrese MJ, Pacreau M, Gaitonde P, Cooke CE, Shaya FT, Rodriguez de Bittner M, University of Maryland School of Pharmacy, Baltimore, MD, USA, University of Paris-Sud, Chatenay-Malabry, France

PHS125 M18 ESTABLISHING SCREENING STRATEGIES FOR PROSTATE CANCER PATIENTS (ESCAPE)

Qureshi Z, Wang L, Chavner R, Glover S, Khan MM, Bennett CL, University of South Carolina, Columbia, SC, USA

PHS126 M19 RACIAL AND ETHNIC DISPARITIES IN MEETING MTM ELIGIBILITY CRITERIA BASED ON STAR RATINGS COMPARED TO MMA

Wang J, Qiao Y, Spivey C, Shih YT, Wan J, Kuhle J, Dagogo-Jack S, Cushman W, Chisholm-Burns M, University of Tennessee Health Science Center College of Pharmacy, Memphis, TN, USA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, The University of Tennessee Health Science Center College of Medicine, Memphis, TN, USA, Pharmacy Quality Alliance, Springfield, VA, USA

PHS127 M20 THE EFFECT OF INSURANCE COVERAGE AND CO-PAYMENT LEVELS ON DILATED EYE EXAMS FOR PATIENTS WITH DIABETES MELLITUS IN A US NATIONAL SAMPLE

An J, Western University of Health Sciences, Pomona, CA, USA

PHS128 M21 DO MEDICAL HOMES INFLUENCE HEALTHCARE UTILIZATION RATES AND PROCESS OF CARE MEASURES?

Singer D, Alcusky M, Hegarty SE, Keith SW, Djatche L, Lombardi M, Maio V, Thomas Jefferson University, Philadelphia, PA, USA, UMass Medical School, Worcester, MA, USA, Parma Local Health Authority, Parma, Italy
SERIOUS PSYCHOLOGICAL DISTRESS AND EMERGENCY DEPARTMENT USE AMONG ADULTS WITH MULTIMORBIDITY IN THE UNITED STATES
Ahluwaisain K1, Meraya AM2, Sambamoorthi U3, West Virginia University, Morgantown, WV, USA, 2West Virginia University, School of Pharmacy, Morgantown, WV, USA

DOES ROUTINE SCREENING FOR CARDIOVASCULAR RISK FACTORS WIDEN SOCIOECONOMIC INEQUALITIES IN HEALTH? : A SYSTEMATIC REVIEW
Tan MM1, Lee JT1, Lorent T1, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, 3University of York, York, UK

INEQUITY IN HEALTHCARE ACCESS IN ASIAN COUNTRIES WITH REPORTEDLY HIGH UNIVERSAL HEALTH COVERAGE LEVELS
Evans JS1, Ma C2, Noon K1, Steeves S1, Costello Medical Consulting Ltd, Cambridge, UK, 2Costello Medical Singapore Pte Ltd, Singapore, Singapore

STATUS ANALYSIS OF HOSPITALIZATION UTILIZATION AMONG DIFFERENT TYPES OF MEDICAL INSTITUTIONS WITHIN BEIJING URBAN EMPLOYEE BASIC MEDICAL INSURANCE SCHEME: A CASE STUDY OF A CERTAIN ONCOLOGY INSTITUTION
Leng JH1, Chen ZS1, Gao GY2, Liu Y1, Zheng QW1, Peking University Cancer Hospital, Beijing, China, 2Capital Medical University, Beijing, China

EFFECT OF PAY-FOR-PERFORMANCE IN PRIMARY HEALTH CARE ON INFANT MORTALITY: EVIDENCE OF SYNTHETIC CONTROL FOR ARGENTINA.
Palacios A, University of Buenos Aires (UBA), Buenos Aires, Argentina

KEYS TO YOUR CARE: A MATERNITY HEALTH PROGRAM DRIVES IMPROVEMENTS IN PRENATAL/POSTPARTUM CARE AND INFANT BIRTH WEIGHTS

TRENDS IN REALIZED ACCESS TO RECOMMENDED CARE AMONG US ADULTS WITH DIABETES
Chhabra S, Farris K, UNIVERSITY OF MICHIGAN, ANN ARBOR, MI, USA

CANCER CENTRE FOLLOW-UP CARE OF CANCER SURVIVORS: A POPULATION-BASED ANALYSIS
Urquhart R, Lethbridge L, Dalhousie University, Halifax, NS, Canada

HEALTH INSURANCE AND FEMALE LABOUR FORCE PARTICIPATION IN RURAL CHINA
Zhang X, University of New South Wales, Sydney, Australia

IDENTIFICATION OF PATIENTS AT-RISK FOR 30-DAY READMISSION WHO SHOULD BE INCLUDED IN PREVENTION INTERVENTIONS: ASSESSMENT OF HOSPITAL AND COMMUNITY HEALTHCARE PROVIDERS
Flaks-Manov N1, Sruolovic E1, Yahalom R2, Peri-Mazra H2, Reem L2, Key C2, Hoshen M1, Balicer RD1, Shadmi E3, Clalit Research Institute, Tel Aviv, Israel, 2Clalit Health Services, Tel-Aviv, Israel, 3University of Haifa, Haifa, Israel

PREVALECE, INCERENTAL COST AND RESOURCE UTILIZATION ASSOCIATED WITH OPIOID OVERDOSES IN THE UNITED STATES
Electricwala BS1, Carroll NV1, Nadpara P1, Cannon E2, Wander C2, Virginia Commonwealth University, Richmond, VA, USA, 2SelectHealth, Murray, UT, USA

HEALTH CARE UTILIZATION AND EXPENDITURES FOR CHILDREN WITH SPECIAL HEALTHCARE NEEDS: A CROSS-SECTIONAL ANALYSIS FOR MEDICAID AND PRIVATE INSURANCE ENROLLEES
Lin C1, Carlin C2, Romley JA1, University of Southern California, Los Angeles, CA, USA, 2Medica Research Institute, Minneapolis, MN, USA

HOSPITALIZATION COST ESTIMATION MODEL USING A MULTILEVEL ANALYSIS
Romero Prada ME1, Celis S1, Acero G2, Gallo D2, Cruz AM3, Salutia Foundation - Research center in economy, management and health technologies, Bogota, Colombia, 2Salutia Foundation - Research center in economy, management and health technologies, Bogota, Colombia, 3Cooomeva EPS, Cali, Colombia

DIRECT COSTS OF MEDICAL CARE FROM INTENSIVE CARE UNITS IN COLOMBIA
Florez Tanus A1, Marrugo Amedo C2, Gomez de la Rosa F3, Lopez Pajarro K4, Mora Jayutt G2, Mazenett Granados E4, Dueñas Castell C5, Alvis Guzman N6, 1Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoléon Franco Pareja. Centro de Investigación e Innovación en salud, Cartagena de Indias, Colombia, 2Universidad de Cartagena. Centro de investigación e innovación en salud-CIIISA, Cartagena de Indias, 3Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoléon Franco Pareja. Centro de Investigación e Innovación en salud, Cartagena de Indias, Colombia, 4Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoléon Franco Pareja. Centro de Investigación e Innovación en salud, Cartagena de Indias, Colombia, 5Universidad de Cartagena. Centro de Investigación y Docencia. Hospital Infantil Napoléon Franco Pareja. Centro de Investigación e Innovación en salud, Cartagena de Indias, Colombia, 6University of Haifa, Haifa, Israel
Colombia, ALZAK Foundation, Cartagena, Colombia, Centro de investigación e Innovación en Salud - CiiSA, Cartagena de Indias, Colombia, ALZAK Foundation. Universidad de Cartagena, Cartagena de Indias, Colombia

**PHS143 N12**

DIRECT AND INDIRECT ECONOMIC BURDEN OF ADULTS WITH RENAL FAILURE: NATIONAL U.S. ESTIMATES USING MEDICAL EXPENDITURE PANEL SURVEY DATA, 2008-2013

Alahmari AK, Almalki ZS, Cavanaugh T1, Guo JJ1, Penm J2, 1University of Cincinnati, Cincinnati, OH, USA, 2The University of Sydney, Camperdown NSW, Australia

**PHS144 N13**

BUDGET IMPACT ANALYSIS ON A PHARMACIST-PROVIDED TRANSITIONAL CARE PROGRAM

Ni W1, Colayco D2, Hashimoto J2, Komoto K2, Gowda C3, Wearda B3, McCombs J1, 1University of Southern California, Los Angeles, CA, USA, 2Synergy Pharmacy Solutions, Bakersfield, CA, USA, 3Kern Health Systems, Bakersfield, CA, USA

**PHS145 N14**

ESTIMATES OF INCREMENTAL HEALTHCARE EXPENDITURES ASSOCIATED WITH DEPRESSION TYPE AND SYMPTOMS AMONG US ADULT POPULATION WITH DIABETES

Chhabra S1, Farris K2, 1University of Michigan, Ann Arbor, MI, USA, 2UNIVERSITY OF MICHIGAN, ANN ARBOR, MI, USA

**PHS146 N15**

MODELING BED NUMBER REQUIREMENTS FOR ISOLATED SURGICAL AORTIC VALVE REPLACEMENT CENTERS

Park LI1, Zemanova B1, Boleckova J2, Moore M1, Candolfi P1, 1Edwards Lifescience, irvine, CA, USA, 2Edwards Lifesciences, Nyon, Switzerland

**PHS147 N16**

IDENTIFICATION OF TYPE 2 DIABETES COST DRIVERS USING MEDICAL BILLING CODES IN ADMINISTRATIVE CLAIMS

Patel CA1, Kozma CM2, Slaton T2, 1Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2CK Consulting Associates, LLC, Saint Helena Island, SC, USA

**PHS148 N17**

COSTS OF HOSPITAL ACQUIRED PRESSURE ULCERS

Malheiro DT, Ayres Fd, Ferreira JC, Ferreira ME, Shiramizo SC, Barros CG, Hospital Israelita Albert Einstein, São Paulo, Brazil

**PHS149 N18**

COST-EFFECTIVENESS ANALYSIS OF SOLID ORGAN TRANSPLANTS IN A PRIVATE, PHILANTHROPIC AND TERTIARY HOSPITAL IN BRAZIL

Malheiro DT1, Matos AC2, Morgado S2, Bacal F1, Junior JE1, Almeida MD1, Filho AP1, Neto MC1, 1Hospital Israelita Albert Einstein, São Paulo, Brazil, 2Hospital israelita albert einstein, Sao Paulo, Brazil

**PHS150 N19**

COSTS AND RESOURCE UTILISATION ASSOCIATED WITH COMORBID CONDITIONS OF TYPE 2 DIABETES PATIENTS IN A SOUTH AFRICAN PRIVATELY MANAGED HEALTHCARE ORGANISATION

Naidoo L1, Butkow N1, Barnard P1, Libhaber E1, Bezuidenhout J2, 1University of Witwatersrand, Johannesburg, South Africa, 2Sanlam Health, Johannesburg, South Africa

**PHS151 N20**

PERSONAL HEALTH DEVICES AND THEIR IMPACT ON HEALTH CARE COSTS AND UTILIZATION AND MEMBER ENGAGEMENT

Olison C, Nelson S, Newell J, Toensing P, Hertzberg J, Optum, Minnetonka, MN, USA

**PHS152 N21**

ECONOMIC EVALUATION OF DIABETES MELLITUS TYPE 2 BURDEN AND IT’S MAIN CARDIOVASCULAR COMPLICATIONS IN THE RUSSIAN FEDERATION

Kontsevaya A1, Karpov O2, Shestakova M3, Belousov Y4, 1State Research Center of Preventive Medicine, Moscow, Russia, Moscow, Russian Federation, 2Sanofi, Moscow, Russian Federation, 3Institute of Diabetes, Moscow, Russian Federation, 4N.I. Pirogov Russian National Research Medical University, Moscow, Russia, Moscow, Russian Federation

**PHS154 N22**

IMMEDIACY TRENDS OF EMERGENCY DEPARTMENT (ED) VISITS, AND FACTORS PREDICTING NON-URGENT AND SEMI-URGENT ED VISITS IN THE UNITED STATES

Siddiqi KA, Haider MR, Demir I, Khan MM, University of South Carolina, Columbia, SC, USA

**PHS155 N23**

COST-EFFECTIVENESS ANALYSIS OF EARLY CANCER SURVEILLANCE FOR PATIENTS WITH LI-FRAUMENI SYNDROME

Tak C1, Biltaji E2, Kohlmann W3, Maese L1, Sherwin C1, Brixner D4, Schiffman J5, 1University of Utah, Salt Lake City, UT, USA, 2University of Utah, Pharmacotherapy Outcomes Research Center, Program in Personalized Health, Salt Lake City, UT, USA, 3Huntsman Cancer Institute, Salt Lake City, UT, USA, 4University of Utah Health Sciences Center, Salt Lake City, UT, USA, 5University of Utah, SALT LAKE CITY, UT, USA

**PHS156 N24**

IMPACT OF AFFORDABLE CARE ACT COVERAGE EXPANSION ON WOMEN'S PREVENTIVE SERVICES

Arora P1, Desai K2, 1University of Wisconsin-Madison, Madison, WI, USA, 2Stanford University, Stanford, CA, USA
CHARACTERIZATION OF SPINAL MUSCULAR ATROPHY POPULATION IN A LARGE US FULLY-INSURED HEALTH PLAN POPULATION

Hall EC1, Wells W1, Juster I2, Mehta R3, Sanquini L2, Biogen, Weston, MA, USA, 2Healthagen, New York, NY, USA

HEALTH CARE PROVIDER AND HEALTH FACILITY FOR ADULT FILIPINO PATIENTS HOSPITALIZED FOR CONGESTIVE HEART FAILURE

Pestano NS1, Tumanan-Mendoza BA2, Mendoza VL1, Punzalan FE3, delos Santos AA1, Natividad RB1, Macabeo R1, Shi L1, Manila Doctors Hospital, Manila, Philippines, 2Manila Doctors Hospital; University of the Philippines College of Medicine, Manila, Philippines, 3Manila Doctors Hospital; University of the Philippines College of Medicine & Philippine General Hospital, Manila, Philippines

KAP ASSESSMENT REGARDING BREAST CANCER: AWARENESS AMONG PAKISTANI FEMALES

Saeed N1, Azhar S1, Khan R2, Bukhari A1, Khalid S2, Syed A1, Saeed H3, 1Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, Pakistan, 2Comsats Abbottabad, Abbottabad, Pakistan, 3COMSATS Institute of Information Technology, Abbottabad, Pakistan

ASSESSMENT OF PUBLIC KNOWLEDGE ABOUT LUNG CANCER IN ABBOTTABAD KPK, PAKISTAN

Khalid S1, Azhar S2, Bukhari A1, Saeed N2, Syed A1, Saeed H3, 1Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, Pakistan, 2Comsats Abbottabad, Abbottabad, Pakistan, 3COMSATS Institute of Information Technology, Abbottabad, Pakistan

HEART RATE RECOVERY IN INFLAMMATORY BOWEL DISEASE (IBD)

Ünsal O, Ünsal Y, Beyan E, Dal K, Bulur O, Uzman M, keçiören research hospital ANKARA /TURKEY, Ankara, Turkey

THE IMPACT OF A CARE MANAGEMENT ENTITY ON PSYCHIATRIC EMERGENCY DEPARTMENT VISITS AND HOSPITALIZATIONS AMONG YOUTH WITH SEVERE MENTAL OR BEHAVIORAL DISORDERS

Tai M1, dosReis S1, Lee B2, Zito JM1, Reeves GM3, Onukwugha E1, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School of Social Work, Baltimore, MD, USA, 3University of Maryland School of Medicine, Baltimore, MD, USA

NEWS AT HOME , A SAFE AND EFFICIENT TRACK AND TRIGGER MECHANISM

Yaya-Oye M1, Emmanuel J2, 1Queen Mary university of London, London, UK, 2Barts health NHS trust and QMUL, London, UK

THE EVALUATION OF MEDICAL BENEFIT SPECIALTY MEDICATION UTILIZATION MANAGEMENT PROGRAM—1-YEAR EXPERIENCE

Lee C1, Chang J2, Lam A2, Eng K2, McCombs J1, 1University of Southern California, Los Angeles, CA, USA, 2PharMedQuest Pharmacy Services, Brea, CA, USA

BREAST CANCER SCREENING PRACTICES IN ASIAN-AMERICAN COMPARED TO NON-HISPANIC WHITE WOMEN: A BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM ANALYSIS

Wei H, Cobran EK, Sattler EL, University of Georgia, Athens, GA, USA

MEDICATION ERRORS (WRONG DOSE ERRORS) IN ADMITTED PEDIATRIC PATIENTS IN SANDEMAN PROVINCIAL HOSPITAL, QUETTA, PAKISTAN

Haq N, Abid Z, Nasim A, Yasmin R, Razaque G, University of Balochistan, Quetta, Pakistan

ASSESSMENT OF KNOWLEDGE, ATTITUDE AND PRACTICE (KAP) OF PHYSICIANS TOWARDS ADVERSE DRUG REACTION (ADR) REPORTING AND PHARMACOVIGILANCE IN PUBLIC HOSPITALS OF QUETTA CITY, PAKISTAN

Anwar M1, ul Haq N1, Ahmed T2, Ahmed N2, 1University of Balochistan, Quetta, Pakistan, 2University of Balochistan, Quetta, Pakistan

IMPACT OF INTRODUCTION OF NEW TECHNOLOGIES FOR MATERNAL FETAL MONITORING AT CLINICA MATERNIDAD RAFAEL CALVO C, CARTAGENA - COLOMBIA

Herrera Rodriguez M1, Edna Estrada F2, Alvis Guzman N2, 1Centro de Investigación para la Salud Materna Perinatal y de la Mujer. Clínica Maternidad Rafael Calvo C, Cartagena de Indias, Colombia, 2Centro de Investigación para la Salud Materna Perinatal y de la Mujer. Clínica Maternidad Rafael Calvo C., Cartagena de Indias, Colombia, 3ALZAK Foundation. Universidad de Cartagena. Centro de Investigación para la Salud Materna, Perinatal y de la Mujer. Clínica Maternidad Rafael Calvo C., Cartagena de Indias, Colombia, 4ALZAK Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia

DRUG UTILIZATION PATTERNS AMONG “HEAVY DRUG USERS” IN AN ELDERLY HOSPITALIZED POPULATION IN PUNJAB, PAKISTAN
A NATIONWIDE SURVEY ON IN-HOSPITAL CLINICAL PHARMACIST’S ACTIVITY IN INFECTION CONTROL TEAM AT A HOSPITAL ALLOWED TO CALCULATE PREFERENTIAL INFECTION PREVENTION COUNTERMEASURE FEE IN JAPAN

Nishimura N1, Hirose M2, Naora K1, Shimane University Hospital, Izumo, Japan, 2Shimane University, Izumo, Japan

A NATIONWIDE SURVEY ON INFECTIO N CONTROL ACTIVITIES WITHIN HOSPITALS ALLOWED TO IMPLEMENT PREFERENTIAL INFECTION PREVENTION COUNTERMEASURE FEE IN JAPAN

Hirose M1, Nishimura N2, Naora K2, Shimane University, Izumo, Japan, 2Shimane University Hospital, Izumo, Japan

ANALYSIS OF CHANGES IN COSTS AND CLAIMS FOR CAPSULE ENDOSCOPY FOLLOWING THE INTRODUCTION OF SELECTIVE HEALTH BENEFIT IN KOREA

Park JH, Yoo My, Jang Is, Hong MY, Kim Ka, HIRA, wonju, Korea, Republic of (South)

ASSOCIATION OF FINANCIAL INCENTIVES WITH PATIENT-CENTERED MEDICAL HOME ADOPTION AMONG PRIMARY CARE PHYSICIANS

Merrell MA, Haider MR, Qureshi Z, University of South Carolina, Columbia, SC, USA

ASSESSMENT OF KNOWLEDGE, ATTITUDE AND PERCEPTION AMONG FUTURE PHARMACISTS TOWARDS PHARMACOVIGILANCE IN PUNJAB, PAKISTAN

Masood I1, Rasool A1, Hassan A2, Javaid S1, Waqas M1, Rehman A1, Saba H1, The Islamia University of Bahawalpur, Bahawalpur, Pakistan, 2Bahawal Victoria Hospital, Bahawalpur, Pakistan

HOSPITAL UTILIZATION PATTERNS AMONG PATIENTS DIAGNOSED WITH PRIMARY BILIARY CIRRHOSIS

Belk K1, Craver CW2, Vizient Inc., Mooresville, NC, USA, 2Vizient Inc., Huntersville, NC, USA

COST CONSEQUENCE ANALYSIS OF A RENAL DISEASE MANAGEMENT MODEL CURRENTLY IMPLEMENTED IN A COLOMBIAN PAYER

Ariza JG1, Bunch A2, Sanabria M3, Ceballos J4, Ardila F5, Cataño A1, Vesga J3, BAXTER, BOGOTA, Colombia, 2Renal Therapy Services, BOGOTA, Colombia, 3RTS, Bogota, Colombia, 4Mederi, BOGOTA, Colombia

ADULT PATIENT SATISFACTION WITH INPATIENT NURSING CARE AND ASSOCIATED FACTORS IN AN ETHIOPIAN REFERRAL HOSPITAL, NORTHEAST, ETHIOPIA

Amdie FZ, Haile K, Adane AA, University of Gondar, Gondar, Ethiopia

HOSPITALIZATIONS AND THE PRIMARY HEALTH PROVIDER IN THE NC MANAGED MEDICAID POPULATION

Carnes KJ, Farrow-Chestnut T, Brandon WP, University of North Carolina at Charlotte, Charlotte, NC, USA

DECREASED RATES OF HEALTH PLAN DISENROLLMENT FOR PATIENTS WITH RHEUMATOID ARTHRITIS

Chung H, Kern DM, Willey V, Quimbo R, Deshpande G, Cochetti PT, HealthCore Inc., Wilmington, DE, USA

RACIAL AND ETHNIC DISPARITIES IN THE UPTAKE OF THE COLORECTAL CANCER SCREENING

Hong Y, Deshmukh AA, University of Florida College of Public Health and Health Professions, Gainesville, FL, USA

PHARMACISTS’ PATIENT SAFETY CULTURE IN JAPAN

Hirose M1, Nishimura N2, Shimane University, Izumo, Japan, 2Shimane University Hospital, Izumo, Japan

APPLICATION OF INDIVIDUAL LEVEL DCE MODEL INTO PATIENT CENTERED CARE: LITERATURE REVIEW AND SIMULATION TEST

Cheng X, University of South Carolina, Columbia, SC, USA

DECREASED RATES OF HEALTH PLAN DISENROLLMENT FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Kern DM, Willey V, Quimbo R, Chung H, Deshpande G, Cochetti PT, HealthCore Inc., Wilmington, DE, USA

FIVE DIMENSIONS TO EVALUATE BREAST CANCER DIAGNOSTIC PROCESS.

Pulido DC1, Alvis LF1, Acuña L2, Bryon A3, Sanchez P1, 1Cuenta de Alto Costo, Bogota D.C., Colombia, 2Cuenta de Alto Costo, Bogotá, Colombia, 3HEORT, Bogota, Colombia

ASSESSMENT OF HEALTHCARE QUALITY AND PATIENT SATISFACTION LEVEL TOWARDS HEALTHCARE SERVICES PROVIDED IN THE HOSPITALS: A CROSS-SECTIONAL SURVEY

Nazir A1, Masood I2, Ahmad M3, Arooj S1, Naz M1, Amir S1, The Islamia University Of Bahawalpur, Bahawalpur, Pakistan, 2The Islamia University of Bahawalpur, Bahawalpur, Pakistan

STUDENTS’ HEALTH STATUS IN A PRIVATE UNIVERSITY OF MALAYSIA: A CROSS-SECTIONAL STUDY
Effectiveness of knowledge translation (KT) interventions to improve patients and community adherence to clinical practice guidelines (Systematic Review)

Garzón-Orjuela N, Eslava-Schmalbach J, Ospina N. National University of Colombia, Bogota, Colombia

KNOWLEDGE OF RISK FACTORS REGARDING THYROID CANCER AMONG COMSATS UNIVERSITY STUDENTS IN ABBOTTABAD PAKISTAN

Iqbal A, Azhar S, Murtaza G, Rashida B, Kalsoom U, Ilyas Z. COMSATS Institute of Information and Technology Abbottabad 22060, Pakistan, Abbottabad, Pakistan, Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, Pakistan

PREDICTION OF HOSPITALIZATION COST IN DIALYSIS PATIENTS

Ariza JG. Bunch A, Ceballos J, Sanabria M, Perez CA, Vesga J, Cataño A, BAXTER, BOGOTA, Colombia, Renal Therapy Services, BOGOTA, Colombia, Mederi, BOGOTA, Colombia, RTS, Bogota, Colombia, Econaclinic, BOGOTA, Colombia

THE EVIDENCE BEHIND ‘CHOOSING WISELY’ RECOMMENDATIONS: A BIBLIOMETRIC ANALYSIS

Chenoweth MD, Tufts University, Medford, MA, USA

A QUALITATIVE STUDY EXPLORING PERCEPTIONS OF POLICY MAKERS ABOUT COMMUNITY PHARMACY PRACTICE AND EXTENDED PHARMACY SERVICES IN LAHORE, PAKISTAN

Hashmi FK. Hassali MA, Saleem F, Babar Zu, Universiti Sains Malaysia, Penang, Malaysia, University of Baluchistan, Quetta, Pakistan, University of Auckland, Auckland, New Zealand

DISEASE STATUS, SYMPTOMOLOGY, AND REMISSION RATES OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND ANKYLOSING SPONDYLITIS PATIENTS IN THE UNITED STATES

Hunter TM. Sandoval D, Lobosco S, Moon R, Birt J, Milligan G, Eli Lilly and Company, Indianapolis, IN, USA, Adelphi Real World, Macclesfield, UK, Adelphi Real World, Bollington, UK

AVAILABILITY OF ESSENTIAL OBSTETRIC DRUGS AND EQUIPMENT AND MATERNAL MORTALITY IN PRIMARY HEALTH CARE SETTING IN INDIA

Sriram S. Khan M. University of South Carolina, Columbia, SC, USA

FACTORS OF CARDIOVASCULAR DISEASE RISK SCREENING UPTAKE AMONG POPULATIONS WITH LOW SOCIOECONOMIC STATUS: A SYSTEMATIC REVIEW

Lim KK, Lim C, Kwan YH, Tan CS, Chan SY, Fong W, Tay HY, Ostbye T, Duke NUS Medical School, Singapore, Singapore, National University of Singapore, Singapore, Singapore, Duke-NUS Medical School, Singapore, Singapore, Singapore General Hospital, Singapore, Singapore, Singapore Heart Foundation, Singapore, Singapore

ASSOCIATION BETWEEN ACCESS TO HEALTH-PROMOTING FACILITIES AND PARTICIPATION IN CARDIOVASCULAR DISEASE (CVD) RISK SCREENING AMONG POPULATIONS WITH LOW SOCIOECONOMIC STATUS (SES) IN SINGAPORE

Lim KK, Lim C, Kwan YH, Ostbye T, Tay HY, Chan SY, Fong W, Tan CS, Duke NUS Medical School, Singapore, Singapore, National University of Singapore, Singapore, Singapore, Duke-NUS Medical School, Singapore, Singapore, Singapore General Hospital, Singapore, Singapore, Singapore Heart Foundation, Singapore, Singapore, Singapore

THE ROLE OF PHARMACISTS IN THE PREVENTION AND TREATMENT OF HOSPITAL-ACQUIRED INFECTIONS

Peasah S. Marshall L. Mercer University College of Pharmacy, Atlanta, GA, USA

AVAILABILITY AND ALLOCATION OF HEALTHCARE SERVICES AND THE EFFECT ON HEALTH OUTCOMES IN FLORIDA: A SPATIAL PERSPECTIVE

Mallow P. University of Cincinnati, Cincinnati, OH, USA

A ZIKA COSTING MODEL FOR SOCIAL INSURANCE SYSTEMS: THE CASE OF THE NATIONAL INSURANCE BOARD OF TRINIDAD AND TOBAGO

Prescod JP. National Insurance Board Trinidad and Tobago, Newtown, Trinidad and Tobago

EVALUATION OF RISK FACTORS AND THE PERCEPTION OF PREGNANT FEMALES REGARDINGS FACTORS ASSOCIATED WITH CAESAREAN IN DIFFERENT HOSPITALS OF QUETTA, PAKISTAN

PHA001
ANALYSIS ON THE CURRENT SITUATION OF HEALTH EDUCATION OF REPRODUCTIVE AGE WOMEN IN SHANGHAI

THE PREVALENCE OF CANCER RELATED DISTRESS AMONG URBAN-DWELLING VETERANS: A PILOT STUDY.

HOSPITAL-LEVEL TRENDS IN PATIENTS’ PERSPECTIVE OF OVERALL EXPERIENCE AS MEASURED THROUGH THE HCAHPS PATIENT SURVEY: ANALYSIS OF HOSPITAL COMPARE DATA (2011-2014)

HOSPITAL-LEVEL TRENDS IN CENTRAL LINE ASSOCIATED BLOODSTREAM INFECTIONS: ANALYSIS OF HOSPITAL COMPARE DATA 2011 - 2013

PHARMACEUTICAL POLICY IN NEPAL: RECENT DEVELOPMENTS AND THE NEED OF PHARMACOECONOMICS

UNITED STATES (US) REAL-WORLD TREATMENT PATTERNS IN ELDERLY PATIENTS WITH NEWLY-DIAGNOSED Glioblastoma (GBM) USING SURVEILLANCE, EPIDEMIOLOGY, AND END RESULRS (SEER)-MEDICARE DATA